<SEC-DOCUMENT>0001683168-25-003575.txt : 20250515
<SEC-HEADER>0001683168-25-003575.hdr.sgml : 20250515
<ACCEPTANCE-DATETIME>20250514185201
ACCESSION NUMBER:		0001683168-25-003575
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20250513
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250515
DATE AS OF CHANGE:		20250514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CNS Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001729427
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				822318545
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39126
		FILM NUMBER:		25947707

	BUSINESS ADDRESS:	
		STREET 1:		2100 WEST LOOP SOUTH
		STREET 2:		SUITE 900
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77027
		BUSINESS PHONE:		1-800-946-9185

	MAIL ADDRESS:	
		STREET 1:		2100 WEST LOOP SOUTH
		STREET 2:		SUITE 900
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77027
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cns_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:CNSP="http://cnspharma.com/20250513">
<head>
     <title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_CNSP_cnspharma.com_20250513 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20250513_20250513 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001729427 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-05-13" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-05-13" id="Fact000004" name="dei:EntityCentralIndexKey">0001729427</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cnsp-20250513.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-05-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001729427</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-13</xbrli:startDate>
        <xbrli:endDate>2025-05-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">___________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>FORM <span id="xdx_90E_edei--DocumentType_c20250513__20250513_zIyStBSmNobg"><ix:nonNumeric contextRef="AsOf2025-05-13" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>Pursuant to Section 13 or 15(d) of the</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>Date of Report (Date of earliest event
reported): <span id="xdx_90F_edei--DocumentPeriodEndDate_c20250513__20250513_zVmVc6ZGJBh"> <ix:nonNumeric contextRef="AsOf2025-05-13" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">May 13, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">___________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>&#160;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b><span id="xdx_905_edei--EntityRegistrantName_c20250513__20250513_zli5LdblQu3l"><ix:nonNumeric contextRef="AsOf2025-05-13" id="Fact000011" name="dei:EntityRegistrantName">CNS Pharmaceuticals, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">(Exact name of registrant as specified in its
charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">___________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_900_edei--EntityIncorporationStateCountryCode_c20250513__20250513_zmGVa7TrDAYj"><ix:nonNumeric contextRef="AsOf2025-05-13" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 32%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityFileNumber_c20250513__20250513_z108lnakBAak"><ix:nonNumeric contextRef="AsOf2025-05-13" id="Fact000013" name="dei:EntityFileNumber">001-39126</ix:nonNumeric></span></b></span></td>
    <td style="width: 34%; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20250513__20250513_z4ZGtbx1keQb"><ix:nonNumeric contextRef="AsOf2025-05-13" id="Fact000014" name="dei:EntityTaxIdentificationNumber">82-2318545</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</p></td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="font-size: 10pt; text-align: center"><span style="font-size: 10pt">(I.R.S. Employer Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b><span id="xdx_901_edei--EntityAddressAddressLine1_c20250513__20250513_zr3Cocw1Sqw2"><ix:nonNumeric contextRef="AsOf2025-05-13" id="Fact000015" name="dei:EntityAddressAddressLine1">2100 West Loop South</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressAddressLine2_c20250513__20250513_zkPC2grA5rCl"><ix:nonNumeric contextRef="AsOf2025-05-13" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 900</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b><span id="xdx_906_edei--EntityAddressCityOrTown_c20250513__20250513_zzrkmX59siC3"><ix:nonNumeric contextRef="AsOf2025-05-13" id="Fact000017" name="dei:EntityAddressCityOrTown">Houston</ix:nonNumeric></span>,
<span id="xdx_90E_edei--EntityAddressStateOrProvince_c20250513__20250513_znsgh1ySwEVj"><ix:nonNumeric contextRef="AsOf2025-05-13" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">Texas</ix:nonNumeric></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20250513__20250513_znukx9T75b0k"><ix:nonNumeric contextRef="AsOf2025-05-13" id="Fact000019" name="dei:EntityAddressPostalZipCode">77027</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">(Address of principal executive offices)
(Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>Registrant&#8217;s telephone number, including
area code: <span id="xdx_903_edei--CityAreaCode_c20250513__20250513_zdnNcHLiSMtf"><ix:nonNumeric contextRef="AsOf2025-05-13" id="Fact000020" name="dei:CityAreaCode">(800)</ix:nonNumeric></span> <span id="xdx_907_edei--LocalPhoneNumber_c20250513__20250513_z3uOvLFLx4gb"><ix:nonNumeric contextRef="AsOf2025-05-13" id="Fact000021" name="dei:LocalPhoneNumber">946-9185</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">(Former Name or Former Address, if Changed
Since Last Report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">___________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (<i>see </i>General Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_edei--WrittenCommunications_c20250513__20250513_z7qt5bD7quG1"><ix:nonNumeric contextRef="AsOf2025-05-13" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;&#160;Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_edei--SolicitingMaterial_c20250513__20250513_zg863opsFkhc"><ix:nonNumeric contextRef="AsOf2025-05-13" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;&#160;Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_edei--PreCommencementTenderOffer_c20250513__20250513_z6a1V2Jg1w9j"><ix:nonNumeric contextRef="AsOf2025-05-13" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;&#160;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_edei--PreCommencementIssuerTenderOffer_c20250513__20250513_zPtryvpKXZh2"><ix:nonNumeric contextRef="AsOf2025-05-13" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span>&#160;&#160;&#160;&#160;&#160;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: right">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20250513__20250513_z4W9h1YMLSkk"><ix:nonNumeric contextRef="AsOf2025-05-13" format="ixt:booleantrue" id="Fact000026" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. &#160;&#160; <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_edei--EntityExTransitionPeriod_c20250513__20250513_zK7SOlKRA2vk"><ix:nonNumeric contextRef="AsOf2025-05-13" format="ixt:booleanfalse" id="Fact000027" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant to Section
12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: Black 1pt solid; padding-left: 0pt; width: 40%; text-align: justify"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 20%; text-align: justify"><span style="font-size: 10pt">Trading Symbols(s)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 40%; text-align: justify"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><span style="font-size: 10pt"><span id="xdx_90F_edei--Security12bTitle_c20250513__20250513_zdMMi1VJvoC5"><ix:nonNumeric contextRef="AsOf2025-05-13" id="Fact000028" name="dei:Security12bTitle">Common stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 10pt"><span id="xdx_90C_edei--TradingSymbol_c20250513__20250513_zTEHgRYlSLYk"><ix:nonNumeric contextRef="AsOf2025-05-13" id="Fact000029" name="dei:TradingSymbol">CNSP</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><span style="font-size: 10pt">The <span id="xdx_903_edei--SecurityExchangeName_c20250513__20250513_zaRgcRpKa5ei"><ix:nonNumeric contextRef="AsOf2025-05-13" format="ixt-sec:exchnameen" id="Fact000030" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Item 1.01. </b></span> <span style="font-size: 10pt"><b>
Entry into a Material Definitive Agreement.</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
May 13, 2025, CNS Pharmaceuticals, Inc., a Nevada corporation (the &#8220;Company&#8221;) entered into a placement agency agreement with
A.G.P./Alliance Global Partners (the &#8220;Placement Agent&#8221;) for the public offering (the &#8220;Offering&#8221;) by the Company
of (i) 325,000 shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;)
(ii) pre-funded warrants to purchase 3,627,570 shares of Common Stock (the &#8220;Pre-Funded Warrants&#8221;); and (iii) Series F Warrants
to purchase up to an aggregate of 3,952,570 shares of Common Stock (the &#8220;Common Warrants&#8221;). The Common Warrants and Pre-Funded
Warrants are collectively referred to herein as the (&#8220;Warrants&#8221;). The combined purchase price of one share of Common Stock
and one accompanying Common Warrant was $1.265 and the combined purchase price of one Pre-Funded Warrant and one accompanying Common Warrant
was $1.264. In connection with the Offering, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;)
with the institutional investor that participated in the Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Subject
to certain ownership limitations, the Warrants are exercisable immediately upon issuance (the &#8220;Initial Exercise Date&#8221;). Each
Pre-Funded Warrant is exercisable into one share of Common Stock at a price per share of $0.001 (as adjusted from time to time in accordance
with the terms thereof) and expire once such Pre-Funded Warrants are fully exercised. The Common Warrants are exercisable into one share
of Common Stock at a price per share of $1.14 (as adjusted from time to time in accordance with the terms thereof) and expire five years
from Initial Exercise Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Warrants may only be exercised on a cashless basis if there is no registration statement registering, or the prospectus contained therein
is not available for, the issuance or resale of shares of Common Stock underlying the Warrants to or by the holder. The holder of a Common
Warrant is prohibited from exercising any Common Warrants to the extent that such exercise would result in the number of shares of Common
Stock beneficially owned by such holder and its affiliates exceeding 4.99% of the total number of shares of Common Stock outstanding immediately
after giving effect to the exercise, which percentage may be increased or decreased at the holder&#8217;s election not to exceed 9.99%.
The holder of a Pre-Funded Warrant is prohibited from exercising any Pre-Funded Warrants to the extent that such exercise would result
in the number of shares of Common Stock beneficially owned by such holder and its affiliates exceeding 9.99%, which percentage may be
increased or decreased at the holder&#8217;s election not to exceed 9.99%. In the event of certain fundamental transactions, the holder
of the Common Warrants will have the right to receive the Black Scholes Value (as defined in the Common Warrants) of its Common Warrants
calculated pursuant to a formula set forth in the Common Warrants, payable either in cash or in the same type or form of consideration
that is being offered and being paid to the holders of Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
closing of the sales of these securities occurred on May 14, 2025 (the &#8220;Closing Date&#8221;). The gross proceeds to the Company
from the Offering were approximately $5.0 million, before deducting the Placement Agent&#8217;s fees and other Offering expenses, and
excluding the proceeds, if any, from the exercise of the Warrants. The Company intends to use the net proceeds from the Offering to fund
working capital and general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company has agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of, any shares of Common
Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock or file any registration statement
or prospectus, or any amendment or supplement thereto for 45 days after the Closing Date, subject to certain exceptions. In addition,
the Company has agreed not to effect or enter into an agreement to effect any issuance of Common Stock or any securities convertible into
or exercisable or exchangeable for shares of Common Stock involving a Variable Rate Transaction (as defined in the Purchase Agreement)
until 180 days after the Closing Date, subject to certain exceptions; provided that commencing on the 46th day following the Closing Date,
the Company will be permitted to make sales under any &#8220;at-the-market offering&#8221; sales agreement with A.G.P./Alliance Global
Partners.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
offering of the Shares and Warrants was made pursuant to a Registration Statement on Form S-1, as amended, (File No. 333-286529) (the
&#8220;Registration Statement&#8221;), which was filed by the Company with the Securities and Exchange Commission on April 14, 2025 and
declared effective on May 13, 2025. The Offering of the Shares and Warrants was made only by means of a prospectus forming a part of the
Registration Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the Placement Agreement, the Company agreed to pay the Placement Agent an aggregate fee equal to 7% of the gross proceeds received
by the Company from the sale of the securities in the transaction. The Company also agreed to reimburse the Placement Agent for (i) up
to $85,000 for the Placement Agent&#8217; legal fees, and (ii) for certain reasonable non-accountable fees and expenses not to exceed
1.0% of the aggregate gross cash proceeds to us from the sale of the securities in the Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
representations, warranties and covenants contained in the Purchase Agreement and Placement Agreement were made solely for the benefit
of the parties to the Purchase Agreement and Placement Agreement. In addition, such representations, warranties and covenants: (i) are
intended as a way of allocating the risk between the parties to such agreements and not as statements of fact, and (ii) may apply standards
of materiality in a way that is different from what may be viewed as material by stockholders of, or other investors in, the Company.
Accordingly, the Purchase Agreement and Placement Agreement are filed with this Current Report on Form 8-K only to provide investors with
information regarding the terms of transaction, and not to provide investors with any other factual information regarding the Company.
Information concerning the subject matter of the representations and warranties may change after the date of the Purchase Agreement or
Placement Agreement, which subsequent information may or may not be fully reflected in public disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
forms of the Purchase Agreement, the Placement Agreement, the Series F Warrant, and the Pre-Funded Warrant are filed as Exhibits 10.1,
1.1, 4.1, and 4.2, respectively, to this Current Report on Form 8-K. The foregoing summaries of the terms of these documents are subject
to, and qualified in their entirety by, such documents, which are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>Item 9.01. Financial Statements
and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"><b>(d) Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; width: 10%"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 88%"><span style="font-size: 10pt"><b>Exhibit Description</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td><span style="font-size: 10pt">1.1</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="cns_ex0101.htm">Placement Agent Agreement dated May 13, 2025 by and between CNS Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners</a> </span></td></tr>
  <tr>
    <td><span style="font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="cns_ex0401.htm">Form of Series F Common Warrant</a></span></td></tr>
  <tr>
    <td><span style="font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="cns_ex0402.htm">Form of Pre-Funded Warrant</a></span></td></tr>
  <tr>
    <td><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="cns_ex1001.htm">Form of Securities Purchase Agreement</a></span></td></tr>
  <tr>
    <td><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Cover page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Signature</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 27pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CNS Pharmaceuticals, Inc.</p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 51%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 35%">&#160;</td>
    <td style="width: 11%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By: </span></td>
    <td style="white-space: nowrap"><span style="font-size: 10pt"><span style="text-decoration: underline">/s/ Chris
    Downs&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chris Downs</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>Dated: May 14, 2025</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>



<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2OtRWu/EyqYgsRCS63XKKJd2R2e3vkXrLNiUaBobhnO8cISZiRUvdIsNhXhVQY9e3yiFUeEZGc0LvyNebDPyt8KKtY2Xc8P7AnDyDnpmFMj16YbDetcUmg2kcySSSKcRJliZQbkXw1XMyZ92gcVq1oEwDJVPPGp3i15hQqycZ6l5D1R7ZajI+LoxH+Q0ynkrY0V09iK8WiiIXwWSYQKyYbr13LZ4OzZeERYudr7Mj/d/gAwXQSos= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>cns_ex0101.htm
<DESCRIPTION>PLACEMENT AGENT AGREEMENT DATED MAY 13, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">May 13, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CNS Pharmaceuticals, Inc.<BR>
Attention: John Climaco<BR>
2100 West Loop South, Suite 900<BR>
Houston, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Mr. Climaco:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This letter (the &ldquo;<B>Agreement</B>&rdquo;)
constitutes the agreement between A.G.P./Alliance Global Partners (&ldquo;<B>A.G.P.</B>&rdquo; or the &ldquo;<B>Placement Agent</B>&rdquo;)
and CNS Pharmaceuticals, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), that the Placement Agent shall serve as the exclusive
placement agent for the Company, on a reasonable &ldquo;best efforts&rdquo; basis, in connection with the proposed placement (the &ldquo;<B>Placement</B>&rdquo;)
of (i) shares (the &ldquo;<B>Shares</B>&rdquo;) of common stock of the Company, par value $0.001 per share (the &ldquo;<B>Common Stock</B>&rdquo;),
(ii) warrants (the &ldquo;<B>Common Warrants</B>&rdquo;) to purchase shares of Common Stock (the &ldquo;<B>Common Warrant Shares</B>&rdquo;)
and (iii) pre-funded warrants (the &ldquo;<B>Pre-Funded Warrants</B>&rdquo; and together with the Shares and Common Warrants, the &ldquo;<B>Securities</B>&rdquo;)
to purchase shares of Common Stock (the &ldquo;<B>Pre-Funded Warrant Shares</B>&rdquo;). The Securities actually placed by the Placement
Agent are referred to herein as the &ldquo;<B>Placement Agent Securities</B>.&rdquo; The terms of the Placement shall be mutually agreed
upon by the Company and the purchasers of the Securities (each, a &ldquo;<B>Purchaser</B>&rdquo; and collectively, the &ldquo;<B>Purchasers</B>&rdquo;),
and nothing herein constitutes that the Placement Agent would have the power or authority to bind the Company or any Purchaser, or an
obligation for the Company to issue any Securities or complete the Placement. The Company expressly acknowledges and agrees that the Placement
Agent&rsquo;s obligations hereunder are on a reasonable &ldquo;best efforts&rdquo; basis only and that the execution of this Agreement
does not constitute a commitment by the Placement Agent to purchase the Securities and does not ensure the successful placement of the
Securities or any portion thereof or the success of the Placement Agent with respect to securing any other financing on behalf of the
Company. The Securities shall be offered and sold under the Company&rsquo;s registration statement on Form S-1 (File No. 333-286529).
The Placement Agent may retain other brokers or dealers to act as sub-agents or selected dealers on its behalf in connection with the
Placement. Certain affiliates of the Placement Agent may participate in the Placement by purchasing some of the Placement Agent Securities.
The sale of Placement Agent Securities to any Purchaser will be evidenced by a securities purchase agreement (the &ldquo;<B>Purchase Agreement</B>&rdquo;)
between the Company and such Purchaser, in a form reasonably acceptable to the Company and the Purchaser. Capitalized terms that are not
otherwise defined herein have the meanings given to such terms in the Purchase Agreement. Prior to the signing of any Purchase Agreement,
officers of the Company will be available to answer inquiries from the prospective Purchasers. The Placement Agent may retain other brokers
or dealers to act as sub-agents or selected-dealers on its behalf in connection with the Placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SECTION 1. <U>REPRESENTATIONS AND WARRANTIES OF THE COMPANY; COVENANTS
OF THE COMPANY</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A. <U>Representations of the
Company</U>. With respect to the Placement Agent Securities, each of the representations and warranties (together with any related disclosure
schedules thereto) and covenants made by the Company to the Purchasers in the Purchase Agreement in connection with the Placement, is
hereby incorporated herein by reference into this Agreement (as though fully restated herein) and is, as of the date of this Agreement
and as of the date of the sale of the Placement Agent Securities (the &ldquo;<B>Closing Date</B>&rdquo;), hereby made to, and in favor
of, the Placement Agent, as applicable. In addition to the foregoing, the Company represents and warrants that there are no affiliations
with any Financial Industry Regulatory Authority (&ldquo;<B>FINRA</B>&rdquo;) member firm among the Company&rsquo;s officers, directors
or, to the knowledge of the Company, any five percent (5.0%) or greater stockholder of the Company, except as set forth in the Purchase
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B. <U>Covenants of the Company</U>.
The Company covenants and agrees to continue to retain (i) a firm of Public Company Accounting Oversight Board independent registered
public accountants for a period of at least two (2) years after the Closing Date and (ii) a reputable transfer agent with respect to the
Common Stock for a period of two (2) years after the Closing Date, provided in each case that the Company is then subject to the reporting
requirement of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;). Furthermore, except as set forth
below, from the date hereof until forty five (45) days after the Closing Date, without the prior written consent of the Placement Agent,
neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance
of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto,
other than filing the final Prospectus and a registration statement on Form S-8 in connection with any employee benefit plan; provided,
however, such restrictions shall not apply with respect to an Exempt Issuance. In addition, from the date hereof until the 180 day anniversary
of the Closing Date, the Company shall not effect or enter into an agreement to effect any issuance of Common Stock or Common Stock Equivalents
involving an at-the-market offering or Variable Rate Transaction (as defined in the Purchase Agreement). No Variable Rate Transaction
shall be an Exempt Issuance. Notwithstanding the foregoing, commencing on the 46<SUP>th</SUP> day following the Closing Date, the Company
will be permitted to make any sales under any &ldquo;at-the-market offering&rdquo; sales agreement with A.G.P./Alliance Global Partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SECTION 2. <U>REPRESENTATIONS OF THE PLACEMENT
AGENT</U>. The Placement Agent each represent and warrant that it (i) is a member in good standing of FINRA, (ii) is registered as a broker/dealer
under the Exchange Act, (iii) is licensed as a broker/dealer under the laws of the United States of America applicable to the offers and
sales of the Placement Agent Securities by the Placement Agent, (iv) is and will be a corporate body validly existing under the laws of
its place of incorporation, and (v) has full power and authority to enter into and perform its obligations under this Agreement. The Placement
Agent will immediately notify the Company in writing of any change in its status with respect to subsections (i) through (v) above. The
Placement Agent each covenant that it will use its reasonable best efforts to conduct the Placement hereunder in compliance with the provisions
of this Agreement and the requirements of applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SECTION 3. <U>COMPENSATION</U>. In consideration
of the services to be provided for hereunder, the Company shall pay to the Placement Agent and/or its respective designees a cash fee
of 7.0% of the aggregate gross proceeds raised from the sale of the Placement Agent Securities (the &ldquo;<B>Cash Fee</B>&rdquo;). Each
of the Placement Agent reserves the right to reduce any item of compensation or adjust the terms thereof as specified herein in the event
that a determination is made by FINRA to the effect that the Placement Agent&rsquo;s aggregate compensation is in excess of that permitted
by FINRA Rules or that the terms thereof require adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SECTION 4. <U>EXPENSES</U>. The Company agrees
to pay all costs, fees and expenses incurred by the Company in connection with the performance of its obligations hereunder and in connection
with the transactions contemplated hereby, including, without limitation: (i) all expenses incident to the issuance, delivery and qualification
of the Placement Agent Securities (including all printing and engraving costs); (ii) all fees and expenses of the registrar and transfer
agent of the Shares; (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Placement
Agent Securities; (iv) all fees and expenses of the Company&rsquo;s counsel, independent public or certified public accountants and other
advisors; (v) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration
Statement (including financial statements, exhibits, schedules, consents and certificates of experts), Preliminary Prospectus and the
Prospectus, and all amendments and supplements thereto, and this Agreement; (vi) all filing fees, reasonable attorneys&rsquo; fees and
expenses incurred by the Company in connection with qualifying or registering (or obtaining exemptions from the qualification or registration
of) all or any part of the Placement Agent Securities for offer and sale under the state securities or blue sky laws or the securities
laws of any other country; (vii) the fees and expenses associated with including the Placement Agent Securities on the Trading Market;
(viii) up to $85,000 for the reasonable, documented, and accountable expenses related to legal fees of counsel to the Placement Agent
specifically incurred in connection with the Placement; (ix) non-accountable expenses in an amount of not more than 1% of the aggregate
gross proceeds of the Placement; and (x) closing costs, which shall include the reimbursement of the reasonable out-of-pocket cost of
the escrow agent or clearing agent, as applicable, in an amount up to $10,000; provided, that this sentence in no way limits or impairs
the indemnification or contribution provisions contained herein. The Placement Agent reserve the right to reduce any item of compensation
or adjust the terms thereof as specified herein in the event that a determination shall be made by FINRA to the effect that the Placement
Agent&rsquo;s aggregate compensation is in excess of FINRA Rules or that the terms thereof require adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SECTION 5. <U>INDEMNIFICATION</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A. To the extent permitted by
law, with respect to the Placement Agent Securities, the Company will indemnify the Placement Agent and its affiliates, stockholders,
directors, officers, employees, members, counsel and controlling persons (within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act) (each such person, an &ldquo;<B>Indemnified Person</B>&rdquo;) against all losses, claims, damages, expenses and
liabilities, as the same are incurred (including the reasonable and documented fees and expenses of counsel) (&ldquo;<B>Claims</B>&rdquo;),
relating to or arising out of its activities hereunder, its status, title or role as Placement Agent, pursuant to this Agreement, except
to the extent that any losses, claims, damages, expenses or liabilities (or actions in respect thereof) are found in a final judgment
(not subject to appeal) by a court of law to have resulted from the Placement Agent&rsquo;s fraud, willful misconduct, gross negligence,
recklessness, or violation of law or insofar as such Claims arise out of or are based upon an untrue statement or omission or alleged
untrue statement or omission in disclosure in the Registration Statement, the Preliminary Prospectus, or the Prospectus furnished to the
Company in writing by the Placement Agent expressly for use therein. Notwithstanding anything set forth herein to the contrary, the Company
agrees to indemnify the Placement Agent and its counsel, Sullivan &amp; Worcester LLP, to the fullest extent set forth in this Section
5, against any and all claims asserted by any or person or entity alleging that the Placement Agent were not permitted or entitled to
act as a placement agent herein, or that the Company was not permitted to hire or retain the Placement Agent herein, including but not
limited to any claims arising out of any purported right of first refusal another person or entity claims to have to act as a placement
agent or any similar role with respect to the Company or its securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B. Promptly after receipt by
the Placement Agent of notice of any claim or the commencement of any action or proceeding with respect to which the Placement Agent is
entitled to indemnity hereunder, the applicable Placement Agent will notify the Company in writing of such claim or of the commencement
of such action or proceeding, but failure to so notify the Company shall not relieve the Company from any obligation it may have hereunder,
except and only to the extent such failure results in the forfeiture by the Company of substantial rights and defenses. If the Company
so elects or is requested by the Placement Agent, the Company will assume the defense of such action or proceeding and will employ counsel
reasonably satisfactory to the applicable Placement Agent and will pay the reasonable fees and expenses of such counsel. Notwithstanding
the preceding sentence, the Placement Agent will be entitled to employ its own counsel separate from counsel for the Company and from
any other party in such action if counsel for the Placement Agent reasonably determines that it would be inappropriate under the applicable
rules of professional responsibility for the same counsel to represent both the Company and the Placement Agent. In such event, the reasonable
and documented fees and disbursements of no more than one (1) such separate counsel will be paid by the Company, in addition to fees of
local counsel. The Company will have the right to settle the claim or proceeding, provided that the Company will not settle any such claim,
action or proceeding without the prior written consent of the Placement Agent (which will not be unreasonably withheld or delayed) unless
such settlement provides for an unconditional and irrevocable release of the Indemnified Persons from any and all liability arising out
of such claim or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C. The Company agrees to notify
the Placement Agent promptly of the assertion against it or any other person of any claim or the commencement of any action or proceeding
relating to a transaction contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">D. If for any reason the foregoing
indemnity is unavailable to the Placement Agent or insufficient to hold the Placement Agent harmless, then the Company shall contribute
to the amount paid or payable by the Placement Agent as a result of such losses, claims, damages or liabilities in such proportion as
is appropriate to reflect not only the relative benefits received by the Company on the one hand and the Placement Agent on the other,
but also the relative fault of the Company on the one hand and the Placement Agent on the other that resulted in such losses, claims,
damages or liabilities, as well as any relevant equitable considerations. The amounts paid or payable by a party in respect of losses,
claims, damages and liabilities referred to above shall be deemed to include any legal or other fees and expenses incurred in defending
any litigation, proceeding or other action or claim. Notwithstanding the provisions hereof, the Placement Agent&rsquo;s share of the liability
hereunder shall not be in excess of the amount of fees actually received, or to be received, by the Placement Agent under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">E. These indemnification provisions
shall remain in full force and effect whether or not the transaction contemplated by this Agreement is completed and shall survive the
termination of this Agreement, and shall be in addition to any liability that the Company might otherwise have to any indemnified party
under this Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SECTION 6. <U>ENGAGEMENT TERM</U>. The Placement
Agent&rsquo; engagement hereunder will be until the earlier of (i) July 15, 2025, 2025 and (ii) the Closing Date (such earlier date, the
&ldquo;<B>Termination Date</B>&rdquo;). In the event, however, in the course of the Placement Agent&rsquo;s performance of due diligence
it deems it necessary to terminate the engagement, the Placement Agent may do so prior to the Termination Date. The Company may elect
to terminate the engagement hereunder for any reason prior to the Termination Date but will remain responsible for fees and expenses pursuant
to Section 3 and Section 4 hereof and fees and expenses with respect to the Placement Agent Securities, if sold in the Placement. Notwithstanding
anything to the contrary contained herein, the provisions concerning the Company&rsquo;s obligation to pay any fees or expenses actually
earned pursuant to Section 3 and Section 4 hereof and the provisions concerning confidentiality, indemnification and contribution, no
fiduciary duty and governing law (including the waiver of the right to trial by jury) contained herein will survive any expiration or
termination of this Agreement. If this Agreement is terminated prior to the completion of the Placement, all fees or expenses due to the
Placement Agent shall be paid by the Company to the Placement Agent on or before the Termination Date (in the event such fees or expenses
are earned or owed as of the Termination Date). The Placement Agent agree not to use any confidential information concerning the Company
provided to the Placement Agent by the Company for any purposes other than those contemplated under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SECTION 7. <U>PLACEMENT AGENT INFORMATION</U>.
The Company agrees that any information or advice rendered by the Placement Agent in connection with this engagement is for the confidential
use of the Company only in their evaluation of the Placement and, except as otherwise required by law, the Company will not disclose or
otherwise refer to the advice or information in any manner without the Placement Agent&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SECTION 8. <U>NO FIDUCIARY RELATIONSHIP</U>. This
Agreement does not create, and shall not be construed as creating rights enforceable by any person or entity not a party hereto, except
those entitled hereto by virtue of the indemnification provisions hereof. The Company acknowledges and agrees that the Placement Agent
are not and shall not be construed as a fiduciary of the Company and shall have no duties or liabilities to the equity holders or the
creditors of the Company or any other person by virtue of this Agreement or the retention of the Placement Agent hereunder, all of which
are hereby expressly waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SECTION 9. <U>CLOSING</U>. The obligations of
the Placement Agent, and the closing of the sale of the Placement Agent Securities hereunder, are subject to the accuracy, when made and
on the Closing Date, of the representations and warranties on the part of the Company contained herein and in the Purchase Agreement,
to the performance by the Company of its obligations hereunder and in the Purchase Agreement, and to each of the following additional
terms and conditions, except as otherwise disclosed to and acknowledged and waived by the Placement Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">A. All corporate proceedings
and other legal matters incident to the authorization, form, execution, delivery and validity of each of this Agreement, the Placement
Agent Securities, and all other legal matters relating to this Agreement and the transactions contemplated hereby with respect to the
Placement Agent Securities shall have been completed or resolved in a manner reasonably satisfactory in all material respects to the Placement
Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">B. The Placement Agent shall
have received from the Company&rsquo;s outside legal counsel, ArentFox Schiff LLP, such counsel&rsquo;s written opinion and negative assurance
letter with respect to the Placement Agent Securities, addressed to the Placement Agent and dated as of the Closing Date, in form and
substance reasonably satisfactory to the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">C. [Reserved]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">D. The Placement Agent shall
have a received customary certificate of the Company&rsquo;s Chief Executive Officer, as to the accuracy of the representations and warranties
contains in the Purchase Agreement, and a certificate of the Company&rsquo;s secretary certifying (i) that each of the Company&rsquo;s
charter documents are true and complete, have not been modified and are in full force and effect; (ii) that the resolutions of the Company&rsquo;s
Board of Directors (or any authorized committee thereof) relating to the Placement are in full force and effect and have not been modified;
and (iii) as to the incumbency of the officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">E. The Shares shall be registered
under the Exchange Act and, as of the Closing Date, the Common Stock and the shares issuable upon exercise of the Warrants shall be listed
and admitted and authorized for trading on the Trading Market or other applicable U.S. national exchange and satisfactory evidence of
such action shall have been provided to the Placement Agent. The Company shall have taken no action designed to terminate, or likely to
have the effect of terminating, the registration of the Shares under the Exchange Act or delisting or suspending from trading the Shares
from the Trading Market or other applicable U.S. national exchange, nor has the Company received any information suggesting that the Commission
or the Trading Market or other U.S. applicable national exchange is contemplating terminating such registration or listing except as otherwise
publicly disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">F. No action shall have been
taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any governmental agency or body which would,
as of the Closing Date, prevent the issuance or sale of the Placement Agent Securities or materially and adversely affect or potentially
and adversely affect the business or operations of the Company; and no injunction, restraining order or order of any other nature by any
federal or state court of competent jurisdiction shall have been issued as of the Closing Date which would prevent the issuance or sale
of the Placement Agent Securities or materially and adversely affect or potentially and adversely affect the business or operations of
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">G. The Company shall have entered
into a Purchase Agreement with each of the several Purchasers of the Placement Agent Securities and such agreements shall be in full force
and effect and shall contain representations, warranties and covenants of the Company as agreed upon between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">H. FINRA shall have raised no
objection to the fairness and reasonableness of the terms and arrangements of this Agreement. In addition, the Company shall, if requested
by the Placement Agent, make or authorize Placement Agent&rsquo;s counsel to make on the Company&rsquo;s behalf, any filing with the FINRA
Corporate Financing Department pursuant to FINRA Rule 5110 with respect to the Placement and pay all filing fees required in connection
therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">I. The Placement Agent shall
have received an executed lock-up agreement from each of the Company&rsquo;s executive officers and directors prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">J. On the date hereof, the Placement
Agent shall have received, and the Company shall have caused to be delivered to the Placement Agent, a letter from Malone Bailey LLP (the
independent registered public accounting firm of the Company), addressed to the Placement Agent, dated as of the date hereof, in form
and substance satisfactory to the Placement Agent. The letter shall not disclose any change in the condition (financial or other), earnings,
operations, business or prospects of the Company from that set forth in the Registration Statement, Preliminary Prospectus, and Prospectus,
in the Placement Agent&rsquo;s judgment, is material and adverse and that makes it, in the Placement Agent&rsquo;s judgment, impracticable
or inadvisable to proceed with the offering of the Placement Agent Securities. On the Closing Date, the Placement Agent shall have received
from Malone Bailey LLP, or such other independent registered public accounting firm of the Company, a letter dated as of the Closing Date,
in form and substance satisfactory to the Placement Agent, to the effect that they reaffirm the statements made in the letter furnished
pursuant to this Section 9(J), except that the specified date referred to therein for the carrying out of procedures shall be no more
than three business days prior to such Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">K. The Placement Agent shall
have received an executed FINRA questionnaire from each of the Company and the Company&rsquo;s executive officers, directors and 5% or
greater securityholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of the conditions specified
in this Section 9 shall not have been fulfilled when and as required by this Agreement, all obligations of the Placement Agent hereunder
may be cancelled by the Placement Agent at, or at any time prior to, the Closing Date. Notice of such cancellation shall be given to the
Company in writing or orally. Any such oral notice shall be confirmed promptly thereafter in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SECTION 10. <U>GOVERNING LAW</U>. This Agreement
will be governed by, and construed in accordance with, the laws of the State of New York applicable to agreements made and to be performed
entirely in such State, without regard to its conflict of laws principles. This Agreement may not be assigned by either party without
the prior written consent of the other party. This Agreement shall be binding upon and inure to the benefit of the parties hereto, and
their respective successors and permitted assigns. Any right to trial by jury with respect to any dispute arising under this Agreement
or any transaction or conduct in connection herewith is waived. Any dispute arising under this Agreement may be brought into the courts
of the State of New York or into the Federal Court located in New York, New York and, by execution and delivery of this Agreement, the
Company hereby accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of aforesaid courts.
Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such suit, action
or proceeding by delivering a copy thereof via overnight delivery (with evidence of delivery) to such party at the address in effect for
notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.
Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. If either party
shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action or proceeding
shall be reimbursed by the other party for its attorney&rsquo;s fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SECTION 11. <U>ENTIRE AGREEMENT/MISCELLANEOUS</U>.
This Agreement embodies the entire agreement and understanding between the parties hereto, and supersedes all prior agreements and understandings,
relating to the subject matter hereof. If any provision of this Agreement is determined to be invalid or unenforceable in any respect,
such determination will not affect such provision in any other respect or any other provision of this Agreement, which will remain in
full force and effect. This Agreement may not be amended or otherwise modified or waived except by an instrument in writing signed by
both the Placement Agent and the Company. The representations, warranties, agreements and covenants contained herein shall survive the
Closing Date of the Placement and delivery of the Placement Agent Securities for three years after the Closing Date. This Agreement may
be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need
not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or a .pdf format file, such signature
shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force
and effect as if such facsimile or .pdf signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SECTION 12. <U>NOTICES</U>. Any and all notices
or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and
effective on the earliest of (a) the date of transmission, if such notice or communication is sent to the email address specified on the
signature pages attached hereto prior to 6:30 p.m. (New York City time) on a business day, (b) the next business day after the date of
transmission, if such notice or communication is sent to the email address on the signature pages attached hereto on a day that is not
a business day or later than 6:30 p.m. (New York City time) on any business day, (c) the third business day following the date of mailing,
if sent by an internationally recognized air courier service, or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SECTION 13. <U>PRESS ANNOUNCEMENTS</U>. The Company
agrees that the Placement Agent shall, on and after the Closing Date, have the right to reference the Placement and the Placement Agent&rsquo;s
role in connection therewith in the Placement Agent&rsquo;s marketing materials and on its website and to place advertisements in financial
and other newspapers and journals, in each case at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please confirm that the foregoing
correctly sets forth our agreement by signing and returning to the Placement Agent the enclosed copy of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><B>A.G.P./ALLIANCE GLOBAL PARTNERS</B></TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: black 1pt solid">/s/ Thomas J. Higgins</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Thomas J. Higgins</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Managing Director</TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><U>Address for Notice</U>:</TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">590 Madison Avenue 28th Floor</TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">New York, New York 10022</TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">Attn: Thomas J. Higgins</TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">Email: </TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="width: 55%">&nbsp;</TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 38%">&nbsp;</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accepted and Agreed to as of<BR>
the date first written above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>CNS PHARMACEUTICALS, INC.</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">By:</TD>
    <TD STYLE="width: 38%; border-bottom: black 1pt solid">/s/ Christoper S. Downs</TD>
    <TD STYLE="width: 55%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD>Christopher S. Downs</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><U>Address for Notice:</U></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">2100 West Loop South, Suite 900</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Houston, Texas</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Attn: John Climaco</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to Placement Agency Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="margin: 0"><B></B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>cns_ex0401.htm
<DESCRIPTION>FORM OF SERIES F COMMON WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>FORM
OF SERIES f COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CNS
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 50%">Warrant Shares: </TD>
    <TD STYLE="vertical-align: top; width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Initial Exercise Date: May 14, 2025</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Issue Date: May 14, 2025</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS SERIES F COMMON STOCK
PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, ___________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on May 14, 2030 (the
&ldquo;<U>Termination Date</U>&rdquo;), but not thereafter, to subscribe for and purchase from <B>CNS Pharmaceuticals, Inc.</B>, a Nevada
corporation (the &ldquo;<U>Company</U>&rdquo;), up to ________ shares of common stock, par value $0.001 per share (the &ldquo;<U>Common
Stock</U>&rdquo;) (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;). The purchase price of one share of Common
Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1. Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated May 13, 2025, among the Company and each purchaser signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section 2. Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">a) <U>Exercise of Warrant</U>.
Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial
Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail
attachment) of the Notice of Exercise in the form annexed hereto as <B>Exhibit A</B> (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within
the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section
2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares
specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless
exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<B>&nbsp;</B>No ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and this Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise
within one (1) Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree
that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of
Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B> For the avoidance
of doubt, there is no circumstance that would require the Company to net cash settle this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">b) <U>Exercise Price</U>.
The exercise price per share of Common Stock under this Warrant shall be $1.14, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">c) <U>Cashless Exercise</U>.
If at the time of exercise hereof there is no effective registration statement registering or the prospectus contained therein is not
available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole or in part, at such
time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal to
the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 5%">(A)</TD>
    <TD STYLE="text-align: center; width: 3%">=</TD>
    <TD STYLE="text-align: justify; width: 82%">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">(B)</TD>
    <TD STYLE="text-align: center">=</TD>
    <TD STYLE="text-align: justify">the Exercise Price, as adjusted hereunder; and</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">(X)</TD>
    <TD STYLE="text-align: center">=</TD>
    <TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Warrant Shares are issued
in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant
Shares shall take on the registered characteristics of this Warrant. The Company agrees not to take any position contrary to this Section
2(c), except to the extent required by applicable law, rules, or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding anything herein to the contrary,
on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed or quoted on a Trading Market and if prices for the
Common Stock are then reported on OTCQB or OTCQX and OTCQB or OTCQX, as applicable, is not a Trading Market, the VWAP of the Common Stock
for such date (or the nearest preceding date) on OTCQB or OTCQX, as applicable, (c) if the Common Stock is not then listed or quoted for
trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency
succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other
cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders
of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall
be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means any day on which the Trading Market is open for trading, including any day on which the Trading Market is open for trading for a
period of time less than the customary time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed or quoted on a Trading Market and
if prices for the Common Stock are then reported on OTCQB or OTCQX, and OTCQB or OTCQX, as applicable, is not a Trading Market, the volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX, as applicable, (c) if the
Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and prices for the Common Stock are then reported on The Pink
Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share
of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent
appraiser selected in good faith by the holders of a majority in interest of the Common Warrants then outstanding and reasonably acceptable
to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">d) [<U>RESERVED</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">e) <U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">i. <U>Delivery of Warrant Shares
Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder
by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit
or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either (A) there
is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder
or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate representing the Warrant
Shares, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares set
forth in the Notice of Exercise to the address specified by the Holder in such Notice of Exercise by the date that is the earliest of
(i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate
Exercise Price to the Company, and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the
Company of the Notice of Exercise (such date, the &ldquo;Warrant Share Delivery Date&rdquo;). Upon delivery of the Notice of Exercise,
the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which
this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise
Price (other than in the case of a cashless exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the number of
Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason
to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay
to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based
on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until
such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent (which may be the
Transfer Agent) that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein,
&ldquo;Standard Settlement Period&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s
primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding
the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 9:00 a.m. (New York City time) on the Initial Exercise
Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver, or cause
to be delivered, the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date, and the
Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise
Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date. The Holder and any assignee, by
acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion
of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time will be less than the
amount stated on the face hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">ii. <U>Delivery of New Warrants
Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender
of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights
of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be
identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">iii. <U>Rescission Rights</U>.
If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant
Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">iv. <U>Compensation for Buy-In
on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if the Company
fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above
pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase
(in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares that the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including
brokerage commissions, if any) for the Warrant Shares so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant
Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the
sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of
this Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed
rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with
its exercise and delivery obligations hereunder. For example, if the Holder purchases shares of Common Stock having a total purchase price
of $11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate sale price giving rise to such purchase
obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000.
The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request
of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available
to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect
to the Company&rsquo;s failure to timely deliver shares of Common Stock upon exercise of this Warrant as required pursuant to the terms
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">v. <U>No Fractional Shares or
Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction
of a share that the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay
a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to
the next whole share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">vi. <U>Charges, Taxes and Expenses</U>.
The issuance and delivery of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form, attached hereto as <B>Exhibit B</B>, duly executed by the Holder and the Company
may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">vii. <U>Closing of Books</U>.
The Company will not close its stockholder books or records in any manner that prevents the timely exercise of this Warrant, pursuant
to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">f) <U>Holder&rsquo;s Exercise
Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion
of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth
on the applicable Notice of Exercise, the Holder (together with (i) the Holder&rsquo;s Affiliates, (ii) any other Persons acting as a
group together with the Holder or any of the Holder&rsquo;s Affiliates, and (iii) any other Persons whose beneficial ownership of Common
Stock would be aggregated with the Holder&rsquo;s for the purposes of determination of beneficial ownership pursuant to Section 13(d)
and Rule 13d-3 of the Exchange Act (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the
Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially
owned by the Holder and its Affiliates and Attribution Parties shall include the number of Warrant Shares issuable upon exercise of this
Warrant with respect to which such determination is being made, but shall exclude the number of Warrant Shares that would be issuable
upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or
Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company
(including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the
limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the
preceding sentence, for purposes of this Section 2(f), beneficial ownership shall be calculated in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(f) applies, the
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission
of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination and shall have no liability for exercises of this Warrant that are not in compliance with the Beneficial Ownership
Limitation, except to the extent the Holder has detrimentally relied on the number of outstanding shares of Common Stock that was provided
in writing by the Company. In addition, a determination as to any group status as contemplated above shall be determined in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, and the Company shall have no obligation
to verify or confirm the accuracy of such determination and shall have no liability for exercises of this Warrant that are not in compliance
with the Beneficial Ownership Limitation, except to the extent the Holder relies on the number of outstanding shares of Common Stock that
was provided by the Company. For purposes of this Section 2(f), in determining the number of outstanding shares of Common Stock, a Holder
may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice
by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written request of a Holder,
the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.
In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of
securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such
number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% of
the Common Stock outstanding immediately after giving effect to the issuance of Warrant Shares issuable upon exercise of this Warrant.
The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(f),
provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the Common Stock outstanding immediately after giving effect
to the issuance of Warrant Shares upon exercise of this Warrant held by the Holder and the provisions of this Section 2(f) shall continue
to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered
to the Company. The provisions of this paragraph shall not be construed and implemented in a manner otherwise than in strict conformity
with the terms of this Section 2(f) to correct this paragraph (or any portion hereof) that may be defective or inconsistent with the intended
Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such
limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. To the extent that this Warrant
is unexercisable as a result of the Holder&rsquo;s Beneficial Ownership Limitation, no alternate consideration is owing to the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3. Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">a) <U>Stock Dividends and
Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution
or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which,
for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding
shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of
Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock
of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares
of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the
number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant
shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant remains unchanged. Any adjustment made pursuant
to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">b) [<U>RESERVED</U>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">c) <U>Subsequent Rights Offerings</U>.
In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents
or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock
(the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights,
the aggregate Purchase Rights that the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant,
issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s right to participate
in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled
to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase
Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its
right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">d) <U>Pro Rata Distributions</U>.
During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets
(or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation,
any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement,
scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant,
then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have
participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, that, to the extent
that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares
of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the
benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">e) <U>Fundamental Transaction</U>.
If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another Person in which the Company is not the surviving entity, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of the Company&rsquo;s assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer
or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of more than 50% of the voting
power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires more than 50% of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(f) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(f) on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the
event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable
at any time concurrently with, or within thirty (30) days after, the consummation of the Fundamental Transaction (or, if later, the date
of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder,
as described below, an amount of consideration equal to the Black Scholes Value (as defined below) of the remaining unexercised portion
of this Warrant on the date of consummation of such Fundamental Transaction, provided, however, that, if the Fundamental Transaction is
not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall only be entitled
to receive from the Company or any Successor Entity as of the date of consummation of such Fundamental Transaction the same type or form
of consideration (and in the same proportion), valued at the Black Scholes Value of the unexercised portion of this Warrant, that is being
offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration
be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from
among alternative forms of consideration in connection with the Fundamental Transaction; provided further, that if holders of Common Stock
of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed
to have received shares of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in
such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option
Pricing Model obtained from the &ldquo;<U>OV</U>&rdquo; function on Bloomberg determined as of the day of consummation of the applicable
Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for
a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the
Termination Date, (B) an expected volatility equal to the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing
a 365-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction,
(C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in
cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the greater
of (x) the last VWAP immediately prior to the public announcement of such Fundamental Transaction and (y) the last VWAP immediately prior
to the consummation of such Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement
of the applicable Fundamental Transaction and the Termination Date, and (E) a zero cost of borrow. The payment of the Black Scholes Value
will be made by wire transfer of immediately available funds within five Trading Days of the Holder&rsquo;s election (or, if later, on
the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which
the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company
under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(a) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant that is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental
Transaction, and with an exercise price that applies the exercise price hereunder to such shares of capital stock (but taking into account
the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock,
such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and that is reasonably satisfactory in form and substance to the
Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that
from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring
to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall
assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor
Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">f) <U>Calculations</U>. All
calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">g) <U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">i. <U>Adjustment to Exercise
Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to
the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant
Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">ii. <U>Notice to Allow Exercise
by Holder</U>. If, while this Warrant is outstanding, (A) the Company declares a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Company declares a special nonrecurring cash dividend on, or a redemption of, the Common Stock, (C) the Company
authorizes the granting to all holders of shares of Common Stock rights or warrants to subscribe for or purchase any shares of capital
stock of any class or of any rights, (D) the approval of any stockholders of the Company is required in connection with a Fundamental
Transaction, or (E) the Company authorizes the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the
Warrant Register of the Company, at least three calendar days prior to the applicable record or effective date hereinafter specified,
a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the shares of Common Stock of record to be entitled to such dividend,
distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger,
sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the
shares of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice
or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such
notice; and provided, further, that no notice shall be required if the information is disseminated in a press release or a document filed
with the Commission. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">iii. <U>Voluntary Adjustment
by the Company</U>. Subject to the rules and regulations of the Trading Market on which the Common Stock is then listed, the Company may
at any time during the term of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price
to any amount and for any period of time deemed appropriate by the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4. Transfer of
Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">a) <U>Transferability</U>.
Subject to compliance with applicable securities law, this Warrant and all rights hereunder (including, without limitation, any registration
rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated
agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if
required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full,
in which case, the Holder shall surrender this Warrant to the Company on the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">b) <U>New Warrants</U>. Subject
to compliance with applicable securities law, this Warrant may be divided or combined with other Warrants upon presentation hereof at
the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to
be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer that may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date
and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">c) <U>Warrant Register</U>.
The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;),
in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual
notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5. Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">a) <U>No Rights as Stockholder
Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as
a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.
Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to Section 2(c) or to
receive cash payments pursuant to Section 2(d)(i) or 2(d)(iv) herein, in no event shall the Company be required to net cash settle an
exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">b) <U>Loss, Theft, Destruction
or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the
loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to this Warrant Shares, and in case of loss,
theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of this Warrant, shall not include the
posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and
deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">c) <U>Saturdays, Sundays,
Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein
shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">d) <U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company covenants that,
during the period this Warrant is outstanding, it will reserve from its authorized and unissued shares of Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares underlying this Warrant. The Company further covenants that its issuance of
this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon
the exercise of this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares
may be issued and delivered as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading
Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares that may be issued and delivered upon
the exercise this Warrant will, upon exercise of this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized,
validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue
thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except and to the extent as
waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any
other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times
in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to
protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company
will (i) not increase the par value of any shares of Common Stock above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant and (iii) use commercially reasonable
efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may
be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before taking any action that
would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company
shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or
bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">e) <U>Jurisdiction</U>. All
questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with
the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">f) <U>Restrictions</U>. The
Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered and the Holder does not utilize
cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">g) <U>Nonwaiver and Expenses</U>.
No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right
or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase
Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, and such failure results in any
material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses
including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">h) <U>Notices</U>. Any notice,
request or other document required or permitted to be given or delivered hereunder shall be delivered in accordance with the notice provisions
of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">i) <U>Limitation of Liability</U>.
No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no
enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of
any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">j) <U>Remedies</U>. The Holder,
in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance
of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by
reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for
specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">k) <U>Successors and Assigns</U>.
Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and
be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions
of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder
or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">l) <U>Amendment</U>. This
Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">m) <U>Severability</U>. Wherever
possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if
any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent
of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">n) <U>Headings</U>. The headings
used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">o) <U>Currency</U>. All dollar
amounts referred to in this Warrant are in United States Dollars (&ldquo;<U>U.S. Dollars</U>&rdquo;). All amounts owing under this Warrant
shall be paid in U.S. Dollars. All amounts denominated in other currencies shall be converted in the U.S. Dollar equivalent amount in
accordance with the Exchange Rate on the date of calculation. &ldquo;Exchange Rate&rdquo; means, in relation to any amount of currency
to be converted into U.S. Dollars pursuant to this Warrant, the U.S. Dollar exchange rate as published in the Wall Street Journal (New
York edition) on the relevant date of calculation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the Company has caused this
Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>CNS PHARMACEUTICALS, INC.</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD STYLE="width: 27%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 61%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name: Christopher S. Downs</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title: Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TO: CNS PHARMACEUTICALS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(1) The undersigned hereby elects to purchase ________
Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment
of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(2) Payment shall take the form of (check applicable
box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">[_] in lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">[_] if permitted the cancellation of such
number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with
respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection
2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(3) Please issue said Warrant Shares in the name
of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Warrant Shares shall be delivered to the following DWAC Account
Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[SIGNATURE OF HOLDER]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">________________________________________________________________________<BR>
<I>Signature of Authorized Signatory of Investing Entity</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_________________________________________________<BR>
Name of Authorized Signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">___________________________________________________________________<BR>
Title of Authorized Signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">____________________________________________________________________<BR>
Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="text-transform: uppercase"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ASSIGNMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>(To assign the foregoing Warrant, execute this form and supply required
information. Do not use this form to exercise the Warrant to purchase Warrant Shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">FOR VALUE RECEIVED, the foregoing Warrant and all
rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(Please Print)</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Address:</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(Please Print)</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Phone Number:</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Email Address:</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Dated: _______________ __, ______</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Holder&rsquo;s Signature:</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Holder&rsquo;s Address:</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>cns_ex0402.htm
<DESCRIPTION>FORM OF PRE-FUNDED WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 4.2</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>FORM
OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>CNS
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 50%">Warrant Shares: </TD>
    <TD STYLE="font-size: 10pt; text-align: right; width: 50%">Initial Exercise Date: May 14, 2025</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">Issue Date: May 14, 2025</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS PRE-FUNDED COMMON STOCK
PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, ___________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and until this Warrant is exercised in full (the &ldquo;<U>Termination
Date</U>&rdquo;), but not thereafter, to subscribe for and purchase from <B>CNS Pharmaceuticals, Inc.</B>, a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;),
up to _______ shares of common stock, par value $0.001 per share (the &ldquo;<U>Common Stock</U>&rdquo;) (as subject to adjustment hereunder,
the &ldquo;<U>Warrant Shares</U>&rdquo;). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1.Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated May 13, 2025, among the Company and each purchaser signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2.Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">a) <U>Exercise of Warrant</U>.
Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial
Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail
attachment) of the Notice of Exercise in the form annexed hereto as <B>Exhibit A</B> (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within
the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section
2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares
specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless
exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise
shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
until the Holder has purchased all of the Warrant Shares available hereunder and this Warrant has been exercised in full, in which case,
the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice
of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of
Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in
an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number
of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one
(1) Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that,
by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant
Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof. </B>For the avoidance
of doubt, there is no circumstance that would require the Company to net cash settle this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">b) <U>Exercise Price</U>.
The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.001 per Warrant Share, was pre-funded to the Company
on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of $0.001
per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The Holder shall not
be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any
reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date. The remaining unpaid
exercise price per Warrant Share under this Warrant shall be $0.001, subject to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">c) <U>Cashless Exercise</U>.
This Warrant may be exercised, in whole or in part, by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled
to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">(A)</TD>
    <TD STYLE="width: 3%">=</TD>
    <TD STYLE="text-align: justify; width: 82%">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;Bloomberg&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(B)</TD>
    <TD>=</TD>
    <TD STYLE="text-align: justify">the Exercise Price, as adjusted hereunder; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(X)</TD>
    <TD>=</TD>
    <TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Warrant Shares are issued
in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant
Shares shall take on the registered characteristics of this Warrant. The Company agrees not to take any position contrary to this Section
2(c), except to the extent required by applicable law, rules, or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed or quoted on a Trading Market and if prices for the
Common Stock are then reported on OTCQB or OTCQX and OTCQB or OTCQX, as applicable, is not a Trading Market, the VWAP of the Common Stock
for such date (or the nearest preceding date) on OTCQB or OTCQX, as applicable, (c) if the Common Stock is not then listed or quoted for
trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency
succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other
cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders
of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall
be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means any day on which the Trading Market is open for trading, including any day on which the Trading Market is open for trading for a
period of time less than the customary time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed or quoted on a Trading Market and
if prices for the Common Stock are then reported on OTCQB or OTCQX, and OTCQB or OTCQX, as applicable, is not a Trading Market, the volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX, as applicable, (c) if the
Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and prices for the Common Stock are then reported on The Pink
Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share
of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent
appraiser selected in good faith by the holders of a majority in interest of the Common Warrants then outstanding and reasonably acceptable
to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">d) <U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">i. <U>Delivery of Warrant
Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the
Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through
its Deposit or Withdrawal at Custodian system (&ldquo;DWAC&rdquo;) if the Company is then a participant in such system and either (A)
there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder
or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate representing the Warrant
Shares, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares set
forth in the Notice of Exercise to the address specified by the Holder in such Notice of Exercise by the date that is the earliest of
(i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate
Exercise Price to the Company, and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the
Company of the Notice of Exercise (such date, the &ldquo;Warrant Share Delivery Date&rdquo;). Upon delivery of the Notice of Exercise,
the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which
this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise
Price (other than in the case of a cashless exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the number of
Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason
to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay
to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based
on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until
such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent (which may be the
Transfer Agent) that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein,
&ldquo;Standard Settlement Period&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s
primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding
the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 9:00 a.m. (New York City time) on the Initial Exercise
Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver, or cause
to be delivered, the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date, and the
Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise
Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date. The Holder and any assignee, by
acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion
of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time will be less than the
amount stated on the face hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ii. <U>Delivery of New Warrants
Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender
of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights
of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be
identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">iii. <U>Rescission Rights</U>.
If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant
Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">iv. <U>Compensation for Buy-In
on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if the Company
fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above
pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase
(in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares that the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including
brokerage commissions, if any) for the Warrant Shares so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant
Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the
sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of
this Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed
rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with
its exercise and delivery obligations hereunder. For example, if the Holder purchases shares of Common Stock having a total purchase price
of $11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate sale price giving rise to such purchase
obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000.
The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request
of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available
to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect
to the Company&rsquo;s failure to timely deliver shares of Common Stock upon exercise of this Warrant as required pursuant to the terms
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">v. <U>No Fractional Shares
or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any
fraction of a share that the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either
pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round
up to the next whole share of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">vi. <U>Charges, Taxes and
Expenses</U>. The issuance and delivery of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or
other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form, attached hereto as <B>Exhibit B</B>, duly executed by the Holder
and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">vii. <U>Closing of Books</U>.
The Company will not close its stockholder books or records in any manner that prevents the timely exercise of this Warrant, pursuant
to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">e) <U>Holder&rsquo;s Exercise
Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion
of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth
on the applicable Notice of Exercise, the Holder (together with (i) the Holder&rsquo;s Affiliates, (ii) any other Persons acting as a
group together with the Holder or any of the Holder&rsquo;s Affiliates, and (iii) any other Persons whose beneficial ownership of Common
Stock would be aggregated with the Holder&rsquo;s for the purposes of determination of beneficial ownership pursuant to Section 13(d)
and Rule 13d-3 of the Exchange Act (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the
Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially
owned by the Holder and its Affiliates and Attribution Parties shall include the number of Warrant Shares issuable upon exercise of this
Warrant with respect to which such determination is being made, but shall exclude the number of Warrant Shares that would be issuable
upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or
Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company
(including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the
limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the
preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission
of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination and shall have no liability for exercises of this Warrant that are not in compliance with the Beneficial Ownership
Limitation, except to the extent the Holder has detrimentally relied on the number of outstanding shares of Common Stock that was provided
in writing by the Company. In addition, a determination as to any group status as contemplated above shall be determined in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, and the Company shall have no obligation
to verify or confirm the accuracy of such determination and shall have no liability for exercises of this Warrant that are not in compliance
with the Beneficial Ownership Limitation, except to the extent the Holder relies on the number of outstanding shares of Common Stock that
was provided by the Company. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder
may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice
by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written request of a Holder,
the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.
In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of
securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such
number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 9.99% of
the Common Stock outstanding immediately after giving effect to the issuance of Warrant Shares issuable upon exercise of this Warrant.
The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e),
provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the Common Stock outstanding immediately after giving effect
to the issuance of Warrant Shares upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue
to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered
to the Company. The provisions of this paragraph shall not be construed and implemented in a manner otherwise than in strict conformity
with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) that may be defective or inconsistent with the intended
Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such
limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. To the extent that this Warrant
is unexercisable as a result of the Holder&rsquo;s Beneficial Ownership Limitation, no alternate consideration is owing to the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3.Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">a) <U>Stock Dividends and
Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution
or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which,
for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding
shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of
Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock
of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares
of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the
number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant
shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant remains unchanged. Any adjustment made pursuant
to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">b) <U>Reserved</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">c) <U>Subsequent Rights Offerings</U>.
In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents
or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock
(the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights,
the aggregate Purchase Rights that the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant,
issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s right to participate
in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled
to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase
Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its
right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">d) <U>Pro Rata Distributions</U>.
During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets
(or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation,
any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement,
scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant,
then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have
participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, that, to the extent
that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares
of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the
benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">e) <U>Fundamental Transaction</U>.
If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another Person in which the Company is not the surviving entity, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of the Company&rsquo;s assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer
or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of more than 50% of the voting
power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires more than 50% of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in
a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all
of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section
3(a) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable
delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant
a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant that
is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the
shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this
Warrant) prior to such Fundamental Transaction, and with an exercise price that applies the exercise price hereunder to such shares of
capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the
value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and that is reasonably satisfactory
in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and
be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction
Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power
of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the
same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">f) <U>Calculations</U>. All
calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">g) <U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">i. <U>Adjustment to Exercise
Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to
the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant
Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ii. <U>Notice to Allow Exercise
by Holder</U>. If, while this Warrant is outstanding, (A) the Company declares a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Company declares a special nonrecurring cash dividend on, or a redemption of, the Common Stock, (C) the Company
authorizes the granting to all holders of shares of Common Stock rights or warrants to subscribe for or purchase any shares of capital
stock of any class or of any rights, (D) the approval of any stockholders of the Company is required in connection with a Fundamental
Transaction, or (E) the Company authorizes the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the
Warrant Register of the Company, at least three calendar days prior to the applicable record or effective date hereinafter specified,
a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the shares of Common Stock of record to be entitled to such dividend,
distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger,
sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the
shares of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice
or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such
notice; and provided, further, that no notice shall be required if the information is disseminated in a press release or a document filed
with the Commission. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of its Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">iii. <U>Voluntary Adjustment
by the Company</U>. Subject to the rules and regulations of the Trading Market on which the Common Stock is then listed, the Company may
at any time during the term of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price
to any amount and for any period of time deemed appropriate by the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4.Transfer of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">a) <U>Transferability</U>.
Subject to compliance with applicable securities law, this Warrant and all rights hereunder (including, without limitation, any registration
rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated
agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if
required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full,
in which case, the Holder shall surrender this Warrant to the Company on the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">b) <U>New Warrants</U>. Subject
to compliance with applicable securities law, this Warrant may be divided or combined with other Warrants upon presentation hereof at
the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to
be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer that may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date
and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">c) <U>Warrant Register</U>.
The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;),
in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual
notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5. Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">a) <U>No Rights as Stockholder
Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as
a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.
Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to Section 2(c) or to
receive cash payments pursuant to Section 2(d)(i) or 2(d)(iv) herein, in no event shall the Company be required to net cash settle an
exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">b) <U>Loss, Theft, Destruction
or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the
loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to this Warrant Shares, and in case of loss,
theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of this Warrant, shall not include the
posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and
deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">c) <U>Saturdays, Sundays,
Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein
shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">d) <U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company covenants that,
during the period this Warrant is outstanding, it will reserve from its authorized and unissued shares of Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares underlying this Warrant. The Company further covenants that its issuance of
this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon
the exercise of this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares
may be issued and delivered as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading
Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares that may be issued and delivered upon
the exercise this Warrant will, upon exercise of this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized,
validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue
thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except and to the extent as
waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any
other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times
in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to
protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company
will (i) not increase the par value of any shares of Common Stock above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant and (iii) use commercially reasonable
efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may
be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before taking any action that
would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company
shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or
bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">e) <U>Jurisdiction</U>. All
questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with
the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">f) <U>Restrictions</U>. The
Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered and the Holder does not utilize
cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">g) <U>Nonwaiver and Expenses</U>.
No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right
or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase
Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, and such failure results in any
material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses
including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">h) <U>Notices</U>. Any notice,
request or other document required or permitted to be given or delivered hereunder shall be delivered in accordance with the notice provisions
of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">i) <U>Limitation of Liability</U>.
No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no
enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of
any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">j) <U>Remedies</U>. The Holder,
in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance
of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by
reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for
specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">k) <U>Successors and Assigns</U>.
Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and
be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions
of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder
or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">l) <U>Amendment</U>. This
Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">m) <U>Severability</U>. Wherever
possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if
any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent
of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">n) <U>Headings</U>. The headings
used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">o) <U>Currency</U>. All dollar
amounts referred to in this Warrant are in United States Dollars (&ldquo;<U>U.S. Dollars</U>&rdquo;). All amounts owing under this Warrant
shall be paid in U.S. Dollars. All amounts denominated in other currencies shall be converted in the U.S. Dollar equivalent amount in
accordance with the Exchange Rate on the date of calculation. &ldquo;Exchange Rate&rdquo; means, in relation to any amount of currency
to be converted into U.S. Dollars pursuant to this Warrant, the U.S. Dollar exchange rate as published in the Wall Street Journal (New
York edition) on the relevant date of calculation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the Company has caused this
Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>CNS PHARMACEUTICALS, INC.</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD STYLE="width: 28%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name: Christopher S. Downs</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title: Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TO: CNS PHARMACEUTICALS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(1) The undersigned hereby elects to purchase ________
Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment
of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(2) Payment shall take the form of (check applicable
box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">[_] in lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">[_] if permitted the cancellation of such number
of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect
to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(3) Please issue said Warrant Shares in the name
of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Warrant Shares shall be delivered to the following DWAC Account
Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>[SIGNATURE OF HOLDER]</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of Investing Entity:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><I>Signature of Authorized Signatory of Investing Entity</I>:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name of Authorized Signatory:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title of Authorized Signatory:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Date:</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>ASSIGNMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>(To assign the foregoing Warrant, execute this form and supply required
information. Do not use this form to exercise the Warrant to purchase Warrant Shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">FOR VALUE RECEIVED, the foregoing Warrant and all
rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address:</P></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Phone Number:</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Email Address:</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Dated:</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Holder&rsquo;s Signature:</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Holder&rsquo;s Address:</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>cns_ex1001.htm
<DESCRIPTION>FORM OF SECURITIES PURCHASE AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is dated as of May 13, 2025, between CNS Pharmaceuticals, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;),
and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo;
and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below),
the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company,
securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE I<BR>
DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1.<U>Definitions</U>. In
addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set
forth in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(m).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Applicable Laws</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(qq).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Auditor</U>&rdquo;
means Malone Bailey LLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Authorizations</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(qq).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Beneficial Ownership
Limitation</U>&rdquo; shall have the meaning ascribed to such term in Section 2.1(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>BHCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(nn).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board of Directors</U>&rdquo;
means the board of directors, or any authorized committee thereof, of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing Date</U>&rdquo;
means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and
all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s obligations
to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the first (1<FONT STYLE="font-size: 10pt"><SUP>st</SUP></FONT>)
Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock</U>&rdquo;
means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter
be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock Equivalents</U>&rdquo;
means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Warrant Shares</U>&rdquo;
means the shares of Common Stock issuable upon exercise of the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Warrants</U>&rdquo;
means Series F Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which
Common Warrants shall be exercisable on the Stockholder Approval Date (as defined herein), provided however, if the Pricing Conditions
(as defined herein) are met, Stockholder Approval (as defined herein) will not be required and the Common Warrants will be exercisable
upon issuance, and have a term of exercise equal to five years commencing from the date of issuance, substantially in the form of Exhibit
B attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company Counsel</U>&rdquo;
means ArentFox Schiff LLP, with offices located at 1301 Avenue of the Americas, 42<FONT STYLE="font-size: 10pt"><SUP>nd</SUP></FONT> Floor,
New York, NY 10019 United States</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure Schedules</U>&rdquo;
means the Disclosure Schedules of the Company delivered concurrently herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure Time</U>&rdquo;
means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight
(New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, unless
otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight (New York City
time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof, unless otherwise
instructed as to an earlier time by the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>DVP</U>&rdquo; shall
have the meaning ascribed to such term in Section 2.1(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>DWAC</U>&rdquo;
shall have the meaning ascribed to such term in Section 2.1(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>EDGAR</U>&rdquo;
means the Commission&rsquo;s Electronic Data Gathering, Analysis and Retrieval System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Environmental Law</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation Date</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(v).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt Issuance</U>&rdquo;
means the issuance of (a) shares of Common Stock, options, restricted stock units, or other equity awards to employees, consultants, contractors,
advisors, officers, or directors of the Company pursuant to any equity incentive plan duly adopted for such purpose, by a majority of
the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for
such purpose for services rendered to the Company, (b) securities upon the exercise or exchange of or conversion of any Securities issued
hereunder and upon exercise of other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and
outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase
the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in
connection with stock splits or combinations) or to extend the term of such securities, (c) shares of Common Stock or securities exercisable
or exchangeable for or convertible into shares of Common Stock sold to employees, directors, consultants, or any of their affiliated entities
in the ordinary course of business or pursuant to agreements or in connection with commitments in place as of the date hereof and (d)
securities issued pursuant to acquisitions, joint ventures, strategic alliances, or other strategic transactions, including without limitation
collaborations or arrangements involving research and development or the sale or licensing of intellectual property, approved by a majority
of the disinterested directors of the Company, except for a transaction in which the Company is issuing securities primarily for the purpose
of raising capital or to an entity whose primary business is investing in securities (for avoidance of doubt, securities issued to a venture
arm of a strategic investor shall be deemed an &ldquo;Exempt Issuance&rdquo;), provided in the case of each of clauses (c) and (d), that
such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that require
or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.12(a) herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Federal Reserve</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(nn).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(k).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Hazardous Substances</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual Property
Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Issuer Free Writing
Prospectus</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(f)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>IT Systems</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(pp).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Lien</U>&rdquo;
means a lien, charge, mortgage, pledge, security interest, claim, right of first refusal, pre-emptive right, or other encumbrance of any
kind whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Lock-Up Agreements</U>&rdquo;
means the lock-up agreements, each dated as of the date hereof in substantially the form of <U>Exhibit A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material Adverse
Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material Permits</U>&rdquo;
shall have the meaning assigned to such term in Section 3.1(r).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Money Laundering
Laws</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(oo).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>OFAC</U>&rdquo;
means the Office of Foreign Assets Control of the U.S. Treasury Department</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Offering</U>&rdquo;
means the offering of the Securities hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per Pre-Funded Warrant
Purchase Price</U>&rdquo; means the Per Share Purchase Price minus $0.001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per Share Purchase
Price</U>&rdquo; equals $1.265, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other
similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Personal Data</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(pp).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement Agency
Agreement</U>&rdquo; means that certain Placement Agency Agreement by and between the Company and the Placement Agent, dated as of the
date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement Agent</U>&rdquo;
means A.G.P./Alliance Global Partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded Warrants</U>&rdquo;
means, collectively, the pre-funded Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section
2.3(a) hereof, in substantially the form of <U>Exhibit C</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Preliminary Prospectus</U>&rdquo;
means the preliminary prospectus included in the Registration Statement at the time the Registration Statement is declared effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pricing Conditions</U>&rdquo;
means that the Per Share Purchase Price or Per Pre-Funded Warrant Purchase Price, as applicable, is such that Stockholder Approval is
not required under the rules of The Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;) because either (i) the offering is an at-the-market
offering under Nasdaq rules and such price equals or exceeds the sum of (a) the applicable &ldquo;Minimum Price&rdquo; per share under
Nasdaq Rule 5635(d) plus (b) $0.125 per whole share of Common Stock underlying the Warrant or (ii) the offering is a discounted offering
where the pricing and discount (including attributing a value of $0.125 per whole share underlying the Warrant) meet the pricing requirements
under Nasdaq&rsquo;s rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Settlement Period</U>&rdquo;
shall have the meaning ascribed to such term in Section 2.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Settlement Securities</U>&rdquo;
shall have the meaning ascribed to such term in Section 2.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition) pending or, to the Company&rsquo;s knowledge, threatened in writing against the Company, a Subsidiary or any of
their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal,
state, county, local or foreign).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed under the Registration Statement complying with Rule 424(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser Party</U>&rdquo;
shall have the meaning ascribed to such term in Section 4.9.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration Statement</U>&rdquo;
means the effective registration statement with the Commission on Form S-1 (File No. 333-286529), as amended, including all information,
documents and exhibits filed with or incorporated by reference into such registration statement, which registers the sale of the Securities
and includes any Rule 462(b) Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required Approvals</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 424</U>&rdquo;
means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 462(b) Registration
Statement</U>&rdquo; means any registration statement prepared by the Company registering additional Securities, which was filed with
the Commission on or prior to the date hereof and became automatically effective pursuant to Rule 462(b) promulgated by the Commission
pursuant to the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Sanctions</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(kk).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means for each Purchaser, the Shares, the Warrants and the Warrant Shares purchased pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short Sales</U>&rdquo;
means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include
locating and/or borrowing shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Stockholder Approval</U>&rdquo;
means such approval as may be required by the applicable rules and regulations of The Nasdaq Stock Market LLC (or any successor entity)
from the stockholders of the Company to consent to any exercise of the Warrants and issuance of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Stockholder Approval
Date</U>&rdquo; means the date on which Stockholder Approval is received and deemed effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription Amount</U>&rdquo;
means, as to each Purchaser, the aggregate amount to be paid for Shares or Pre-Funded Warrants (in lieu of Shares) and Common Warrants
purchased hereunder as specified below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription
Amount,&rdquo; in U.S. dollars and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
and &ldquo;<U>Subsidiaries</U>&rdquo; means any subsidiary of the Company as set forth on Schedule 3.1(a) and shall, where applicable,
also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means The Nasdaq Capital Market (or any nationally recognized successor thereto); provided, however, that in the event the Company&rsquo;s
Common Stock is ever listed or traded on The Nasdaq Global Market, The Nasdaq Global Select Market, The New York Stock Exchange, NYSE
American, NYSE Arca, the OTC Bulletin Board, or the OTCQX or the OTCQB operated by the OTC Markets Group, Inc. (or any nationally recognized
successor to any of the foregoing), then the &ldquo;Trading Market&rdquo; shall mean such other market or exchange on which the Company&rsquo;s
Common Stock is then listed or traded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction Documents</U>&rdquo;
means this Agreement, the Warrants, and the Lock-Up Agreements, all exhibits and schedules thereto and hereto and any other documents
or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer Agent</U>&rdquo;
means Continental Stock Transfer and Trust, the current transfer agent of the Company, with a mailing address of 1 State Street 30th Floor,
New York, NY 10004-1561, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Variable Rate Transaction</U>&rdquo;
shall have the meaning ascribed to such term in Section 4.12(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Common Warrants and the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant Shares</U>&rdquo;
means, collectively, the Common Warrant Shares and the Pre-Funded Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE II<BR>
PURCHASE AND SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1.<U>Closing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) On the Closing Date,
upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery of this
Agreement by the parties hereto, the Company agrees to sell, and each Purchaser, severally and not jointly, agrees to purchase, (i)
the number of shares of Common Stock set forth under the heading &ldquo;Subscription Amount&rdquo; on the Purchaser&rsquo;s
signature page hereto, at the Per Share Purchase Price, and (ii) Common Warrants exercisable for shares of Common Stock as
calculated pursuant to Section 2.2(a). Notwithstanding anything herein to the contrary, to the extent that a Purchaser determines,
in its sole discretion, that as a result of such Purchaser&rsquo;s Subscription Amount, such Purchaser (together with such
Purchaser&rsquo;s Affiliates and any Person acting as a group together with such Purchaser or any of such Purchaser&rsquo;s
Affiliates) would beneficially own shares of Common Stock in excess of the Beneficial Ownership Limitation, the Purchaser may elect
to purchase Pre-Funded Warrants in lieu of the Shares as determined pursuant to Section 2.3(a). The &ldquo;<U>Beneficial Ownership
Limitation</U>&rdquo; shall be 4.99% (or, at the election of the Purchaser, 9.99%) of the number of shares of Common Stock
outstanding immediately after giving effect to the issuance of the Securities on the Closing Date. In each case, the election to
receive Pre-Funded Warrants is solely at the option of the Purchaser; provided, however, the Purchaser shall receive Pre-Funded
Warrants at the option of the Company if necessary to avoid a stockholder vote in connection with the purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Purchaser shall deliver
to the Company, via wire transfer, immediately available funds equal to such Purchaser&rsquo;s Subscription Amount as set forth on the
signature page hereto executed by such Purchaser shall be made available for Delivery Versus Payment (&ldquo;<U>DVP</U>&rdquo;) settlement
with the Company or its designees. The Company shall deliver to each Purchaser its respective Shares and Warrants as determined pursuant
to Section 2.3(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing.
Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur remotely via the exchange
of documents and signatures or such other location as the parties shall mutually agree. Unless otherwise directed by the Placement Agent,
settlement of the Shares shall occur via DVP (<I>i.e.</I>, on the Closing Date, the Company shall issue the Shares registered in the Purchasers&rsquo;
names and addresses and released by the Transfer Agent directly to the account(s) at the Placement Agent identified by each Purchaser;
upon receipt of such Shares, the Placement Agent shall promptly electronically deliver such Shares to the applicable Purchaser, and payment
therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer to the Company). Unless otherwise directed by the
Placement Agent, the Warrants shall be issued to each Purchaser in originally signed form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) Notwithstanding
anything herein to the contrary, if at any time on or after the time of execution of this Agreement by the Company and an applicable
Purchaser through, and including the time immediately prior to, the Closing (the &ldquo;<U>Pre-Settlement Period</U>&rdquo;), such
Purchaser sells to any Person all, or any portion, of any Securities to be issued hereunder to such Purchaser at the Closing
(collectively, the &ldquo;<U>Pre-Settlement Securities</U>&rdquo;), such Person shall, automatically hereunder (without any
additional required actions by such Purchaser or the Company), be deemed to be a Purchaser under this Agreement unconditionally
bound to purchase, and the Company shall be deemed unconditionally bound to sell, such Pre-Settlement Securities to such Purchaser
at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Securities to such Person prior to
the Company&rsquo;s receipt of the purchase price for such Pre-Settlement Securities hereunder; and provided, further, that the
Company hereby acknowledges and agrees (i) that the foregoing shall not constitute a representation or covenant by such Purchaser as
to whether or not such Purchaser will elect to sell any Pre-Settlement Securities during the Pre-Settlement Period and (ii) that any
such decision to sell any shares of Common Stock by such Purchaser shall solely be made at the time such Purchaser elects to effect
any such sale, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2. <U>Deliveries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) On or prior to the
Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) this Agreement duly executed
by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) a legal opinion of Company
Counsel, in form and substance reasonably satisfactory to the Placement Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii) the Company&rsquo;s
wire instructions, on Company letterhead and executed by the Company&rsquo;s Chief Executive Officer or Chief Financial Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iv) subject to the penultimate
sentence of Section 2.1(a), a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on
an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) Shares equal
to the number of shares of Common Stock set forth on such Purchaser&rsquo;s signature page hereto, registered in the name of such Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(v) an originally signed Common
Warrant registered in the name of such Purchaser to purchase up to the number of shares of Common Stock equal to 100% of such Purchaser&rsquo;s
Shares plus the Prefunded Warrant Shares underlying such Purchaser&rsquo;s Pre-Funded Warrant on the date hereof, with an exercise price
equal to $$0.001, subject to adjustment as set forth therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(vi) if applicable, an originally
signed Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to the portion
of such Purchaser&rsquo;s Subscription Amount applicable to Pre-Funded Warrants divided by the Per Pre-Funded Warrant Purchase Price,
with an exercise price equal to $0.001, subject to adjustment therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(vii) the Preliminary Prospectus
and the Prospectus (which may be delivered in accordance with Rule 172 under the Securities Act);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(viii) Lock-up Agreements,
in form and substance reasonably acceptable to the Placement Agent and the Purchasers, executed by each of the Company&rsquo;s executive
officers, directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ix) an Officer&rsquo;s Certificate,
in form and substance reasonably satisfactory to the Placement Agent; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(x) a Secretary&rsquo;s Certificate,
in form and substance reasonably satisfactory to the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) On or prior to the
Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) this Agreement duly
executed by such Purchaser; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) such
Purchaser&rsquo;s Subscription Amount, which shall be made available for DVP settlement with the Company or its designees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) At the time this
Agreement is executed, the Placement Agent shall have received:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) from the Auditor a
cold comfort letter containing statements and information of the type customarily included in accountants&rsquo; comfort letters
with respect to the financial statements and certain financial information contained in the Registration Statement, the Preliminary
Prospectus and the Prospectus, or any Issuer Free Writing Prospectus, addressed to the Placement Agent and in form and substance
satisfactory in all respects to the Placement Agent, dated as of the date of this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) from the Chief
Financial Officer of the Company, a certificate certifying as to certain financial matters set forth therein and in form and
substance satisfactory in all respects to the Placement Agent, dated as of the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) On the Closing Date,
the Placement Agent shall have received:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) from the Auditor a
letter, dated as of the Closing Date, to the effect that the Auditor reaffirms the statements made in the letter furnished pursuant
to Section 2.2(c)(i)); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) from the Chief
Financial Officer of the Company, a certificate, dated as of the Closing Date, to the effect that the Chief Financial Officer of the
Company reaffirms the statements made in the certificate furnished pursuant to Section 2.2(c)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3.<U>Closing Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) The obligations of
the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) the accuracy in all
material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect (as
defined below), in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained
herein (unless such representation or warranty is as of a specific date therein in which case they shall be accurate as of such
date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) all obligations,
covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii) the delivery by
each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) The respective
obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) the accuracy in all
material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all
respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless such
representation or warranty is as of a specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) all obligations,
covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii) the delivery by
the Company of the items set forth in Section 2.2(a) of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iv) there shall have
been no Material Adverse Effect with respect to the Company since the date hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(v) from the date hereof
to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Trading Market on which it
is currently listed, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by
such service, or on any Trading Market, nor shall a banking moratorium have been declared either by U.S. or New York State
authorities, nor shall there have occurred after the date of this Agreement any material outbreak or escalation of hostilities or
other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market
which, in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities
at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE III<BR>
REPRESENTATIONS AND WARRANTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1. <U>Representations
and Warranties of the Company</U>. The Company hereby makes the following representations and warranties to each Purchaser in
addition to the information included in the Disclosure Schedules attached hereto, which Disclosure Schedules shall be deemed a part
hereof and shall qualify any representation or warranty made herein to the extent of the disclosure contained in the corresponding
section of the Disclosure Schedules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company (each, a &ldquo;<U>Subsidiary</U>&rdquo;, and collectively, the
&ldquo;<U>Subsidiaries</U>&rdquo;) are as set forth on Schedule 3.1(a). The Company owns, directly or indirectly, all of the capital
stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of
capital stock or equity interests, as applicable, of each Subsidiary are validly issued and are fully paid, non-assessable and free
of preemptive rights. There are no outstanding options, warrants, scrips or rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or
giving any Person any right to subscribe for or acquire, any capital stock or equity interests, as applicable, of any Subsidiary, or
contracts, commitments, understandings or arrangements by which any Subsidiary is or may become bound to issue capital stock or
equity interests, as applicable. If the Company has no Subsidiaries, all other references to the Subsidiaries or any of them in the
Transaction Documents shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>Organization and
Qualification</U>. Each of the Company and the Subsidiaries has been duly organized and validly exists as a corporation, limited
partnership or company in good standing (or the foreign equivalent thereof, if any) under the laws of its jurisdiction of
organization. The Company and each of the Subsidiaries is duly qualified to do business and is in good standing as a foreign or
extra-provincial corporation, partnership, company or limited liability company in each jurisdiction in which the character or
location of its properties (owned, leased or licensed) or the nature or conduct of its business makes such qualification necessary,
except for those failures to be so qualified or in good standing which (individually and in the aggregate) would not have a Material
Adverse Effect. No Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke,
limit or curtail such power and authority or qualification. Neither the Company nor any Subsidiary is in violation nor default of
any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter
documents. The term &ldquo;<U>Material Adverse Effect</U>&rdquo; means a material adverse effect on (i) the business, general
affairs, management, condition (financial or otherwise), results of operations, stockholders&rsquo; equity, assets, properties or
prospects of the Company and the Subsidiaries, taken as a whole, (ii) the legality, validity or enforceability of any Transaction
Document, or (iii) the Company&rsquo;s ability to perform in any material respect on a timely basis its obligations under any
Transaction Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) <U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and
thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the
consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part
of the Company and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in
connection herewith or therewith other than in connection with the Required Approvals (as defined below). This Agreement and each
other Transaction Document to which the Company is a party has been (or upon delivery will have been) duly executed by the Company
and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company
enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable
bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo;
rights generally, (ii) as limited by general equitable principles and laws relating to the availability of specific performance,
injunctive relief or other equitable remedies, and (iii) insofar as indemnification and contribution provisions may be limited by
applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) <U>No Conflicts</U>.
The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party,
the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and
will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles of
incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar
adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt
or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any
Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to
the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or
other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and
state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected;
except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) <U>Filings, Consents
and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make
any filing or registration with, any court or other federal, state (including state blue sky law), local or other governmental
authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents,
other than: (i) the filings required pursuant to Section 4.5 of this Agreement, (ii) the filing with the Commission of the
Prospectus, (iii) the Stockholder Approval, (iv) notices and/or application(s) to and approvals by each applicable Trading Market
for the listing of the Shares and Warrant Shares for trading thereon in the time and manner required thereby, and (v) filings
required by the Financial Industry Regulatory Authority (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) Issuance of the
Shares and Warrant Shares; Qualification; Registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) The Shares and
Warrant Shares are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be
duly and validly issued, fully paid and non-assessable, free and clear of all Liens imposed by the Company, except for restrictions
set forth in the Transaction Documents. The Warrants are duly authorized and, when issued in accordance with this Agreement, will be
binding obligations of the Company under the law of the jurisdiction governing the Warrants, duly and validly issued, and free and
clear of all Liens imposed by the Company, except for restrictions set forth in the Transaction Documents. The Company has reserved
from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant to this Agreement and the
Warrants. The Securities are not and will not be subject to the preemptive rights of any holders of any security of the Company or
similar contractual rights granted by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) The Company has
prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which Registration
Statement was declared effective on May 13, 2025, including the Preliminary Prospectus, and such amendments and supplements thereto
as may have been required to the date of this Agreement. The Registration Statement is effective under the Securities Act and no
stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the
Preliminary Prospectus or the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted
or, to the knowledge of the Company, are threatened by the Commission. The Company shall file the Preliminary Prospectus and the
Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto became
effective as determined under the Securities Act, at the date of this Agreement and at the Closing Date, the Registration Statement
and any amendments thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not
and will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time
the Preliminary Prospectus, the Prospectus or any amendment or supplement thereto was issued and at the Closing Date, conformed and
will conform in all material respects to the requirements of the Securities Act and did not and will not contain an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any &ldquo;issuer free writing
prospectus&rdquo; (as defined in Rule 433 under the Securities Act) relating to the Securities is hereafter referred to as an &ldquo;<U>Issuer
Free Writing Prospectus</U>&rdquo;. Any reference herein to the Preliminary Prospectus and the Prospectus shall be deemed to refer to
and include the documents incorporated by reference therein as of the date of filing thereof; and any reference herein to any &ldquo;amendment&rdquo;
or &ldquo;supplement&rdquo; with respect to any of the Preliminary Prospectus and the Prospectus shall be deemed to refer to and include
(i) the filing of any document with the Commission incorporated or deemed to be incorporated therein by reference after the date of filing
of such Preliminary Prospectus or Prospectus and (ii) any such document so filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All references in this Agreement
to the Registration Statement, the Preliminary Prospectus, the Prospectus, or any Issuer Free Writing Prospectus, or any amendments or
supplements to any of the foregoing, shall be deemed to include any copy thereof filed with the Commission on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) <U>Securities Act
Compliance</U>. The Registration Statement complies, and the Prospectus and any further amendments or supplements to the
Registration Statement or the Prospectus will comply, in all material respects, with the applicable provisions of the Securities
Act. Each part of the Registration Statement, when such part became effective, did not contain an untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. The
Prospectus, as of its filing date, and any amendment thereof or supplement thereto, did not and will not contain an untrue statement
of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) <U>No Stop
Orders.</U> No order preventing or suspending the use of the Registration Statement, the Preliminary Prospectus or any Issuer Free
Writing Prospectus has been issued by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) <U>Capitalization.</U>
The equity capitalization of the Company is as set forth in the Registration Statement and the SEC Reports as of the dates indicated
therein. All of the issued and outstanding shares of Common Stock are fully paid and non-assessable and have been duly and validly
authorized and issued, in compliance with all applicable federal and state securities laws and not in violation of or subject to any
preemptive or similar right that entitles any person to acquire from the Company any Common Stock or other security of the Company
or any security convertible into, or exercisable or exchangeable for, Common Stock or any other such security, except for such
rights as may have been fully satisfied or waived prior to the date hereof. Except as set forth on <U>Schedule 3.1(i)</U>, or as a
result of the issuance and sale of the Securities, the Company has not issued any capital stock since its most recently filed SEC
Report. Except as set forth on <U>Schedule 3.1(i)</U>, or as a result of the issuance and sale of the Securities, the Company has no
outstanding options, warrants, scrips or rights to subscribe to, calls or commitments of any character whatsoever relating to, or
securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe
for or acquire, any Common Stock, or contracts, commitments, understandings or arrangements by which the Company is or may become
bound to issue additional Common Stock or Common Stock Equivalents and no Person has any right of first refusal, pre-emptive right,
right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents, except
for such rights as may have been fully satisfied or waived prior to the date hereof. Except as set forth on <U>Schedule 3.1(i)</U>,
the issuance and sale of the Securities will not obligate the Company to issue Common Stock or other securities to any Person (other
than the Purchasers) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange
or reset price under any of such securities. There are no outstanding securities or instruments of the Company with any provision
that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the
Company (other than in connection with a stock split, recapitalization, or similar transaction). There are no outstanding securities
or instruments of the Company that contain any redemption or similar provisions, and there are no contracts, commitments,
understandings or arrangements by which the Company is or may become bound to redeem an equity security of the Company. The Company
does not have any stock appreciation rights or &ldquo;phantom share&rdquo; plans or agreements or any similar plan or agreement. All
of the outstanding shares of the Company are duly authorized, validly issued, fully paid and non-assessable, have been issued in
compliance with all federal and state securities laws where applicable, and none of such outstanding shares was issued in violation
of any preemptive rights or similar rights to subscribe for or purchase securities. Except for the Required Approvals, no further
approval or authorization of any shareholder, the Board of Directors or others is required for the issuance and sale of Securities.
Except as set forth in the SEC Reports, there are no stockholders agreements, voting agreements or other similar agreements with
respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among
any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j) <U>Reports</U>. The
Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the
Securities Act and Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two (2) years preceding the date
hereof (or such shorter period as the Company was required by law or regulation to file such materials) (the foregoing materials,
including the exhibits thereto and documents incorporated by reference therein, together with the Preliminary Prospectus and the
Prospectus, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received a valid
extension (or waiver from the Commission) of such time of filing and has filed any such SEC Reports prior to the expiration of any
such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the
Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a
material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject
to Rule 144(i) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k) <U>Financial
Statements</U>. The consolidated financial statements of the Company, including the notes thereto, included or incorporated by
reference in the Registration Statement and the Prospectus comply in all material respects with applicable accounting requirements
and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements
have been prepared in accordance with accounting principles generally accepted in the United States (&ldquo;<U>GAAP</U>&rdquo;)
applied on a consistent basis during the periods involved, except as may be otherwise specified in such financial statements or the
notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in
all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and
the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal,
immaterial, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l) <U>Material Changes;
Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest consolidated financial statements included in or
incorporated by reference into the Registration Statement, the Preliminary Prospectus and the Prospectus, except as set forth ion
Schedule 3.1(l), (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result
in a Material Adverse Effect, (ii) neither the Company nor any Subsidiary has incurred any liabilities (contingent or otherwise)
other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B)
liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made
with the Commission, (iii) the Company has not altered its method of accounting in any material respect, (iv) the Company has not
declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any
agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any
executive officer, director or Affiliate, except pursuant to existing Company stock option or omnibus incentive plans. The Company
does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of the
Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence or development has occurred or exists
or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses,
prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under
applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least one
(1) Trading Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m) <U>Litigation</U>.
Except as set forth in on Schedule 3.1(m), there is no action, suit, inquiry, notice of violation, Proceeding or investigation
pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective
properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state,
county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;) that (i) adversely affects or challenges the legality,
validity or enforceability of any of the Transaction Documents or the Securities or (ii) would, if there were an unfavorable
decision, have or reasonably be expected to result in a Material Adverse Effect. Except as set forth on Schedule 3.1(m), neither the
Company nor any Subsidiary, nor any director or executive officer thereof, is or has been the subject of any Action involving a
claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty, which could result
in a Material Adverse Effect. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any
investigation by the Commission involving the Company or any current or former director or executive officer of the Company. The
Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the
Company or any Subsidiary under the Exchange Act or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(n) <U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the
Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its
Subsidiaries&rsquo; employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such
Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and
its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive
officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment
contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or
agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does
not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and
its Subsidiaries are in compliance with all applicable U.S. federal, state, local and foreign laws and regulations relating to
employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in
compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(o) <U>Compliance</U>.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been
waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the
Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan
or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court,
arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any
governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental
protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case of (i),
(ii) and (iii) as could not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(p) <U>Environmental
Law</U>. There has been no storage, generation, transportation, handling, use, treatment, disposal, discharge, emission,
contamination, release or other activity involving any kind of hazardous, toxic or other wastes, pollutants, contaminants, petroleum
products or other hazardous or toxic substances, chemicals or materials (&ldquo;<U>Hazardous Substances</U>&rdquo;) by, due to, on
behalf of, or caused by the Company or any Subsidiary (or, to the Company&rsquo;s knowledge, any other entity for whose acts or
omissions the Company is or may be liable) upon any property now or previously owned, operated, used or leased by the Company or any
Subsidiary, or upon any other property, that would be a violation of or give rise to any liability under any applicable law, rule,
regulation, order, judgment, decree or permit, common law provision or other legally binding standard relating to pollution or
protection of human health and the environment (&ldquo;<U>Environmental Law</U>&rdquo;), except for violations and liabilities
which, individually or in the aggregate, would not have a Material Adverse Effect. There has been no disposal, discharge, emission
contamination or other release of any kind at, onto or from any such property or into the environment surrounding any such property
of any Hazardous Substances with respect to which the Company or any Subsidiary has knowledge, except as would not, individually or
in the aggregate, have a Material Adverse Effect. There is no pending or, to the best of the Company&rsquo;s knowledge, threatened
administrative, regulatory or judicial action, claim or notice of noncompliance or violation, investigation or proceedings relating
to any Environmental Law against the Company or any Subsidiary, except as would not, individually or in the aggregate, have a
Material Adverse Effect. To the best of the Company&rsquo;s knowledge, no property of the Company or any Subsidiary is subject to
any Lien under any Environmental Law, except as would not, individually or in the aggregate, have a Material Adverse Effect. Except
as disclosed in the Prospectus, neither the Company nor any Subsidiary is subject to any order, decree, agreement or other
individualized legal requirement related to any Environmental Law, that, in any case (individually or in the aggregate), would have
a Material Adverse Effect. The Company and each Subsidiary has all permits, authorizations and approvals required under any
applicable Environmental Laws and are each in compliance with their requirements, except as would not, individually or in the
aggregate, have a Material Adverse Effect. In the ordinary course of its business, the Company periodically reviews the effect of
Environmental Laws on the business, operations and properties of the Company and the Subsidiaries and identifies and evaluates
associated costs and liabilities (including, without limitation, any capital or operating expenditures required for clean-up,
closure or remediation of properties or compliance with Environmental Laws, or any permit, license or approval, any related
constraints on operating activities and any potential liabilities to third parties). On the basis of such review, the Company has
reasonably concluded that such associated costs and liabilities would not, individually or in the aggregate, have a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(q) <U>Title to
Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and
good and marketable title in all personal property owned by them that is material to the business of the Company and the
Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property
and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and
(ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance
with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities currently held
under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the
Company and the Subsidiaries are in compliance in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(r) <U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC
Reports, except where the failure to possess such permits would not reasonably be expected to result in a Material Adverse Effect
(&ldquo;<U>Material Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating
to the revocation or modification of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(s) <U>Intellectual
Property</U>. Except as set forth in the Registration Statement, the Preliminary Prospectus and the Prospectus, to the
Company&rsquo;s knowledge, the Company and the Subsidiaries have, or have rights to use (or can acquire on reasonable terms), all
patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights,
licenses and other intellectual property rights and similar rights necessary or required for use in connection with their respective
businesses as described in the Registration Statement, the Preliminary Prospectus and the Prospectus and which the failure to so
have could reasonably be expected to have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property
Rights</U>&rdquo;). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of,
the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned,
within two (2) years from the date of this Agreement except as would not reasonably be expected to have a Material Adverse Effect.
Neither the Company nor any Subsidiary has received, since the date of the latest financial statements included within or
incorporated by reference into the Registration Statement, the Preliminary Prospectus and the Prospectus, a written notice of a
claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person or is
aware of any facts which would form a reasonable basis for any such claim, except as could not have or reasonably be expected to not
have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is
no existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken
reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where
failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. None of the
Intellectual Property Rights used by the Company or any of its Subsidiaries in their respective businesses has been obtained or is
being used by the Company or such Subsidiary in violation of any contractual obligation binding on the Company or any of its
subsidiaries in violation of the rights of any person. The Company and its subsidiaries have taken all reasonable steps in
accordance with normal industry practice to protect and maintain the Intellectual Property Rights including, without limitation, the
execution of appropriate nondisclosure and invention assignment agreements. The consummation of the transactions contemplated by
this Agreement will not result in the loss or impairment of, or payment of, and additional amounts with respect to, nor require the
consent of, any other person regarding the Company&rsquo;s or any of its subsidiaries&rsquo; right to own or use any of the
Intellectual Property Rights as owned or used in the conduct of such party&rsquo;s business as currently conducted. To the knowledge
of the Company and its Subsidiaries, no employee of any of the Company or its subsidiaries is the subject of any pending claim or
proceeding involving a violation of any term of any employment contract, invention disclosure agreement, patent disclosure
agreement, noncompetition agreement, non-solicitation agreement, nondisclosure agreement or restrictive covenant to or with a former
employer, where the basis of such violation relates to such employee&rsquo;s employment with the Company or its subsidiaries or
actions undertaken by the employee while employed with the Company or its Subsidiaries. The Company has no knowledge of any facts
that would preclude it from having valid license rights or clear title to the Intellectual Property Rights. The Company has no
knowledge that it lacks or will be unable to obtain any rights or licenses to use all Intellectual Property Rights that are
necessary to conduct its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(t) <U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but
not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. Neither the Company
nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such
coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a
significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(u) <U>Transactions With
Affiliates and Employees</U>. Except as set forth on Schedule 3.1(u), none of the executive officers or directors of the Company or
any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to
any transaction with the Company or any Subsidiary (other than for services as employees, executive officers and directors),
including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of
real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring
payments to or from any executive officer, director or such employee or, to the knowledge of the Company, any entity in which any
executive officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder,
member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered,
(ii) reimbursement for expenses incurred on behalf of the Company or a Subsidiary and (iii) other employee benefits, including stock
option agreements under any stock option or omnibus incentive plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(v) <U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with all applicable requirements of the
Sarbanes-Oxley Act of 2002, as amended, except as disclosed in the SEC Reports, the Registration Statement, the Preliminary
Prospectus and the Prospectus. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to
provide reasonable assurance that: (i) transactions are executed in accordance with management&rsquo;s general or specific
authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP
and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&rsquo;s general or
specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals
and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed
such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files
or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the
Commission&rsquo;s rules and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure
controls and procedures of the Company and the Subsidiaries as of applicable dates specified under the Exchange Act (such date, the
&ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange Act the
conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations
as of the Evaluation Date. Except as set forth in the Registration Statement, the Preliminary Prospectus and the Prospectus, since
the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the
Exchange Act) of the Company and the Subsidiaries that have materially affected, or is reasonably likely to materially affect, the
internal control over financial reporting of the Company and the Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(w) <U>Certain Fees</U>.
Except for fees payable to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions are or will be payable by the
Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other
Person with respect to the transactions contemplated by the Transaction Documents. Other than to Persons engaged by any Purchaser,
the Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons
for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction
Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(x) <U>Investment
Company</U>. The Company is not, and immediately after receipt of payment for the Securities, will not be required to register as an
&ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its
business in a manner so that it will not be required to register as an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(y) <U>Registration
Rights</U>. Except as set forth in the SEC Reports, the Registration Statement, the Preliminary Prospectus and the Prospectus, no
Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of
the Company or any Subsidiary that has not been satisfied or waived prior to the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(z) <U>Listing and
Maintenance Requirements</U>. The Company is subject to the reporting requirements of Section 13 of the Exchange Act and files
periodic reports with the Commission; the Common Stock is registered with the Commission under Section 12(b) of the Exchange Act and
the Company is not in breach of any filing or other requirements under the Exchange Act. The Company has not received any notice
from that the Commission is contemplating terminating such registration. Except as set forth in the SEC Reports, the Registration
Statement, the Preliminary Prospectus and the Prospectus, the Company has not, in the 12 months preceding the date hereof, received
notice from any Trading Market on which the Common Stock are or have been listed or quoted to the effect that the Company is not in
compliance with the listing or maintenance requirements of such Trading Market. Except as set forth in the SEC Reports, the
Registration Statement, the Preliminary Prospectus and the Prospectus, the Company is, and has no reason to believe that it will not
in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is
currently eligible for electronic transfer through The Depository Trust Company or another established clearing corporation and the
Company is current in payment of the fees to The Depository Trust Company (or such other established clearing corporation) in
connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(aa) <U>Application of Takeover
Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control
share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover
provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its jurisdiction of incorporation
that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising
their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s issuance of the Securities
and the Purchasers&rsquo; ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(bb) <U>Disclosure</U>. Except
with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information
that it believes constitutes or might constitute material, non-public information that is not otherwise disclosed in the Preliminary Prospectus
or the Prospectus. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions
in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and
its Subsidiaries, their respective businesses and the transactions contemplated hereby, including pursuant to the SEC Reports and the
Disclosure Schedules to this Agreement, is true and correct in all material respects and does not contain any untrue statement of a material
fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under
which they were made, not misleading. The press releases disseminated by the Company during the twelve (12) months preceding the date
of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made and when
made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect
to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(cc) <U>No Integrated Offering</U>.
Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, neither the Company, nor any of
its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or
solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior
offerings by the Company for purposes of (i) the Securities Act, or (ii) except as set forth in the SEC Reports, any applicable stockholder
approval provisions of any Trading Market on which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(dd) <U>Solvency</U>. Based
on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company of the
proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds the amount that
will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known contingent liabilities)
as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on its business as now conducted
and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted
by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the
Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated
uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid.
The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts
of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances that lead it to believe
that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one (1) year
from the Closing Date. All outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or
any Subsidiary has commitments, is set forth on <U>Schedule 3.1(dd)</U>. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo;
means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary
course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or
not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except guaranties by
endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the
present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither
the Company nor any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ee) <U>Tax Status.</U> Except
for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the
Company and its Subsidiaries each (i) has made or filed all U.S. federal, state and local income and all foreign tax returns, reports
and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental assessments and charges,
fines or penalties that are material in amount, shown or determined to be due on such returns, reports and declarations and (iii) has
set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which
such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority
of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ff) <U>Foreign Corrupt Practices;
Criminal Acts.</U> Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person
acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment
or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government
officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully
any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which
is in violation of law, or (iv) violated in any material respect any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(gg) <U>Accountants</U>. The
Company&rsquo;s independent registered public accounting firm is as set forth in the Prospectus. To the knowledge and belief of the Company,
such accounting firm is a registered public accounting firm as required by the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(hh) <U>Acknowledgment Regarding
Purchasers&rsquo; Purchase of Securities.</U> The Company acknowledges and agrees that each of the Purchasers is acting solely in the
capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company
further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with
respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective
representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental
to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s decision
to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions
contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii) <U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding
(except for Sections 3.2(e) and 4.15 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has
been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short,
securities of the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the
Securities for any specified term; (ii) past or future open market or other transactions by any Purchaser, specifically including,
without limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future securities
offering transactions, may negatively impact the market price of the Company&rsquo;s publicly-traded securities; (iii) any
Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser is a party, directly or
indirectly, presently may have a &ldquo;short&rdquo; position in the Common Stock, and (iv) each Purchaser shall not be deemed to
have any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction. The
Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities (in material
compliance with applicable laws) at various times during the period that the Securities are outstanding, and (z) such hedging
activities (if any) could reduce the value of the existing stockholders&rsquo; equity interests in the Company at and after the time
that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not
constitute a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(jj) <U>Regulation M Compliance</U>.
The Company has not, and to its knowledge no one acting on its behalf (other than the Placement Agent, as to which no representation is
made) has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price
of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any
compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting
another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement
Agent pursuant to the Placement Agency Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(kk) <U>Office of Foreign
Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent, employee
or affiliate of the Company or any Subsidiary is currently subject to any &ldquo;<U>Sanctions</U>,&rdquo; which shall include but are
not limited to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;)
and the Company will not, directly or indirectly, use the proceeds of the Offering hereunder, or lend, contribute or otherwise make available
such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person
currently subject to any Sanctions, including but not limited to U.S. sanctions administered by OFAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ll) <U>Stock Option and Omnibus
Incentive Plans.</U> Each stock option granted by the Company under the Company&rsquo;s stock option or omnibus incentive plan, or as
an inducement grant outside of such plan, was granted (i) in accordance with the terms of such plan, or under its terms, respectively,
and (ii) with an exercise price at least equal to the fair market value of the Common Stock on the date such stock option would be considered
granted under GAAP and applicable law. No stock option granted under the Company&rsquo;s stock option or omnibus incentive plan has been
backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly grant, stock
options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material
information regarding the Company or the Subsidiaries or their financial results or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(mm) <U>U.S. Real Property
Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning of Section
897 of the U.S. Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(nn) <U>Bank Holding Company
Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as amended
(the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal Reserve</U>&rdquo;).
Neither the Company nor any of its Subsidiaries owns or controls, directly or indirectly, five percent (5%) or more of the outstanding
shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of a bank or any entity that is subject
to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries exercises a controlling influence
over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(oo) <U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in all
material respects with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions
Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder
(collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;), and no action, suit or proceeding by or before any court or
governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money
Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(pp) <U>Information Technology</U>.
The Company&rsquo;s, the Subsidiaries&rsquo; information technology assets and equipment, computers, systems, networks, hardware, software,
websites, applications, and databases (collectively, &ldquo;<U>IT Systems</U>&rdquo;) operate and perform in all material respects as
required in connection with the operation of the business of the Company and the Subsidiaries as currently conducted. The Company, the
Subsidiaries maintain commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential
information and the integrity, continuous operation, redundancy and security of all IT Systems and all personal, personally identifiable,
sensitive, confidential or regulated data (&ldquo;<U>Personal Data</U>&rdquo;) processed and stored thereon, and to the knowledge of the
Company, there have been no breaches, incidents, violations, outages, compromises or unauthorized uses of or accesses to same, except
as would not reasonably be expected to have a Material Adverse Effect. The Company and the Subsidiaries have implemented backup and disaster
recovery technology consistent with industry standards and practices, and are presently in compliance in all material respects with all
applicable laws or statutes and all applicable judgments, orders, rules and regulations of any court or arbitrator or governmental or
regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data
and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification, except for
any such noncompliance that would not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(qq) <U>Regulatory</U>. Except
as described on Schedule 3.1 (qq), the Company and its Subsidiaries (i) are and at all times have been in material compliance with all
statutes, rules and regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution,
marketing, advertising, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or
distributed by the Company including, without limitation the Federal Food, Drug and Cosmetic Act (21 U.S.C. &sect; 301 et seq.), the federal
Anti-Kickback Statute (42 U.S.C. &sect; 1320a-7b(b)), the Health Insurance Portability and Accountability Act of 1996, as amended by the
Health Information Technology for Economic and Clinical Health Act of 2009, and the Patient Protection and Affordable Care Act of 2010,
as amended by the Health Care and Education Affordability Reconciliation Act of 2010, the regulations promulgated pursuant to such laws,
and any successor government programs and comparable state laws, regulations relating to Good Clinical Practices and Good Laboratory Practices
and all other local, state, federal, national, supranational and foreign laws, manual provisions, policies and administrative guidance
relating to the regulation of the Company (collectively, the &ldquo;<U>Applicable Laws</U>&rdquo;); (ii) have not received any notice
from any court or arbitrator or governmental or regulatory authority or third party alleging or asserting noncompliance with any Applicable
Laws or any licenses, exemptions, certificates, approvals, clearances, authorizations, permits, registrations and supplements or amendments
thereto required by any such Applicable Laws (&ldquo;<U>Authorizations</U>&rdquo;); (iii) possess all material Authorizations and such
Authorizations are valid and in full force and effect and are not in violation of any term of any such Authorizations; (iv) have not received
written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation arbitration or other action from any court
or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of
any Applicable Laws or Authorizations nor is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration
or other action threatened; (v) have not received any written notice that any court or arbitrator or governmental or regulatory authority
has taken, is taking or intends to take, action to limit, suspend, materially modify or revoke any Authorizations nor is any such limitation,
suspension, modification or revocation threatened; (vi) have filed, obtained, maintained or submitted all material reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations
and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete
and accurate on the date filed (or were corrected or supplemented by a subsequent submission); and (vii) are not a party to any corporate
integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental
or regulatory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(rr) <U>Promotional Stock
Activities</U>. Neither the Company nor any Subsidiary of the Company and none of their respective officers, directors, managers, affiliates
or agents have engaged in any stock promotional activity that could give rise to a complaint, inquiry, or trading suspension by the SEC
alleging: (i) a violation of the anti-fraud provisions of the federal securities laws; (ii) violations of the anti-touting provisions;
(iii) improper &ldquo;gun-jumping&rdquo;; or (iv) promotion without proper disclosure of compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2.<U> Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of
the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall
be accurate as of such date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good
standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction
Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction
Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized
by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser.
Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in
accordance with the terms hereof or thereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable
against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights
generally; (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies; and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>Understandings or
Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect
arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement
or otherwise in compliance with applicable federal and state securities laws).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) <U>Experience of
Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in
the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an
investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) <U>Access to
Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all
exhibits and schedules thereto) and the SEC Reports, the Registration Statement and the Preliminary Prospectus, and has been
afforded: (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of
the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the
Securities; (ii) access to information about the Company and its financial condition, results of operations, business, properties,
management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional
information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed
investment decision with respect to the investment. Such Purchaser acknowledges and agrees that the Placement Agent, nor any
Affiliate of the Placement Agent, has provided such Purchaser with any information or advice with respect to the Securities nor is
such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes any representation
as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public
information with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance of
the Securities to such Purchaser, the Placement Agent, nor any of its Affiliates has acted as a financial advisor or fiduciary to
such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) <U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor
has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such
Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth
the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage
separate portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions
made by the portfolio managers managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall
only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the
Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser&rsquo;s
representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and
Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction
(including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing
contained herein shall constitute a representation or warranty against, or a prohibition of, any actions with respect to the
borrowing of, arrangement to borrow, identification of the availability of, and/or securing of, securities of the Company in order
for such Purchaser (or its broker or other financial representative) to effect Short Sales or similar transactions in the
future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) <U>No Voting
Agreements</U>. The Purchaser is not a party to any agreement or arrangement, whether written or oral, between the Purchaser and any
other Purchaser and any of the Company&rsquo;s stockholders as of the date hereof, regulating the management of the Company, the
stockholders&rsquo; rights in the Company, the transfer of shares in the Company, including any voting agreements, stockholder
agreements or any other similar agreement, even if its title is different or has any other relations or agreements with any of the
Company&rsquo;s stockholders, directors or officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) <U>Brokers</U>.
Except as set forth in the Prospectus, no agent, broker, investment banker, person or firm acting in a similar capacity on behalf of
or under the authority of the Purchaser is or will be entitled to any broker&rsquo;s or finder&rsquo;s fee or any other commission
or similar fee, directly or indirectly, for which the Company or any of its Affiliates after the Closing could have any liabilities
in connection with this Agreement, any of the transactions contemplated by this Agreement, or on account of any action taken by the
Purchaser in connection with the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) <U>Independent
Advice</U>. Each Purchaser understands that nothing in this Agreement or any other materials presented by or on behalf of the
Company to the Purchaser in connection with the purchase of the Securities constitutes legal, tax or investment advice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company acknowledges and
agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on
the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties contained in any
other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation
of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute
a representation or warranty, or preclude any actions, except as set forth in this Agreement, with respect to locating or borrowing shares
in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE IV<BR>
OTHER AGREEMENTS OF THE PARTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1. <U>Legends</U>. The
Shares and, if all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the
issuance of the Warrant Shares or if the Warrant is exercised via cashless exercise, the Warrant Shares shall be issued free of all
restrictive legends. If at any time following the date hereof the Registration Statement (or any subsequent registration statement
registering the sale or resale of the Warrant Shares) is not effective or is not otherwise available for the initial sale by the
Company of the Shares, the Warrants or the Warrant Shares, the Company shall immediately notify the holders of the Warrants in
writing that such registration statement is not then effective and thereafter shall promptly notify such holders when the
registration statement is effective again and available for the initial sale by the Company of the Shares, the Warrants or the
Warrant Shares (it being understood and agreed that the foregoing shall not limit the ability of the Company to issue, or any
Purchaser to sell, any of the Shares, the Warrants or the Warrant Shares in compliance with applicable federal and state securities
laws). The Company shall use commercially reasonable efforts to keep a registration statement (including the Registration Statement)
registering the issuance of the Warrant Shares effective during the term of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2. <U>[Reserved.] </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3. <U>Furnishing of
Information; Public Information</U>. Until the earliest of the time that (i) no Purchaser owns Securities and (ii) the Common
Warrants have expired, the Company covenants to maintain the registration of the Common Stock under Section 12(b) or 12(g) of the
Exchange Act and to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports
required to be filed by the Company after the date hereof pursuant to the Exchange Act, even if the Company is not then subject to
the reporting requirements of the Exchange Act, except in the event that the Company consummates (in each case on or after the date
as of which the Purchasers may sell all of their Securities without restriction or limitation pursuant to Rule 144) (a) any
transaction or series of related transactions as a result of which any Person (together with its Affiliates) acquires then
outstanding securities of the Company representing more than fifty percent (50%) of the voting control of the Company; (b) a merger
or reorganization of the Company with one or more other entities in which the Company is not the surviving entity; or (c) a sale of
all or substantially all of the assets of the Company, where the consummation of such transaction results in the Company no longer
subject to the reporting requirements of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4. <U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in
Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules and
regulations of any Trading Market such that it would require stockholder approval prior to the closing of such other transaction
unless stockholder approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5. <U>Securities Laws
Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time issue a press release disclosing the material terms of the
transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto
as deemed by Company Counsel, with the Commission within the time required by the Exchange Act. From and after the issuance of such
press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information
delivered to any of the Purchasers by the Company or any of the Subsidiaries or Affiliates, or any of their respective officers,
directors, employees or agents in connection with the transactions contemplated by the Transaction Documents. In addition, effective
upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations
under any agreement, whether written or oral, between the Company, any of the Subsidiaries or any of their respective officers,
directors, agents, employees or Affiliates, including without limitation, the Placement Agent, on the one hand, and any of the
Purchasers or any of their Affiliates on the other hand, with respect to the transactions contemplated hereby shall terminate and be
of no further force or effect. The Company and each Purchaser shall consult with each other in issuing any other press releases with
respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor
otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any
Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not
unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly
provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company
shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any
regulatory agency or applicable Trading Market, without the prior written consent of such Purchaser, except (a) as required by
federal securities law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such
disclosure is required by applicable law or Trading Market regulations, in which case the Company shall provide the Purchasers with
prior notice of such disclosure permitted under this clause (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6. <U>Stockholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any
Purchaser is an &ldquo;Acquiring Person&rdquo; under any control share acquisition, business combination, poison pill (including any
distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company,
or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities
under the Transaction Documents or under any other agreement between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7. <U>Non-Public
Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be disclosed pursuant to Section 4.5, the Company covenants and agrees that neither it, nor any other Person
acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company
reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the
receipt of such information and agreed with the Company to keep such information confidential. The Company understands and confirms
that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent
that the Company delivers any material, non-public information to a Purchaser without such Purchaser&rsquo;s consent, the Company
hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of the Subsidiaries,
or any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company, any of the Subsidiaries
or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis of, such material,
non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided
pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any
Subsidiaries, the Company shall simultaneously with the delivery of such notice file such material non-public information on with
the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying
on the foregoing covenant in effecting transactions in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.8. <U>Use of
Proceeds</U>. Except as set forth in the Preliminary Prospectus or the Prospectus, the Company shall use the net proceeds from the
sale of the Securities hereunder for working capital and general corporate purposes and shall not use such proceeds: (a) for the
satisfaction of any portion of the Company&rsquo;s debt (other than payment of trade payables and accrued liabilities in the
ordinary course of the Company&rsquo;s business and repayment of obligations outstanding as of the date of this Agreement and
consistent with prior practices), (b) for the redemption of any Common Stock or Common Stock Equivalents, (c) for the settlement of
any outstanding litigation, or (d) in violation of FCPA or OFAC regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.9. <U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section 4.9, the Company will indemnify and hold each Purchaser and its
directors, officers, stockholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such
Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers,
stockholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding
such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser
Party</U>&rdquo;) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses,
including all judgments, amounts paid in settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation
that any such Purchaser Party may suffer or incur caused by or based upon (a) any material breach of any of the representations or
warranties made by the Company in this Agreement or in the other Transaction Documents (b) any action instituted against a Purchaser
Party in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of
such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (except to the extent such
action is solely based upon a material breach of such Purchaser Party&rsquo;s representations, warranties or covenants under the
Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations
by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party that is finally judicially
determined to constitute fraud, gross negligence or willful misconduct). If any action shall be brought against any Purchaser Party
in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in
writing, and the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable
to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in
the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent
that (x) the employment thereof has been specifically authorized by the Company in writing, (y) the Company has failed after a
reasonable period of time to assume such defense and to employ counsel or (z) in such action there is, in the reasonable opinion of
counsel to the applicable Purchaser Party, a material conflict on any material issue between the position of the Company and the
position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more
than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (1) for any settlement by
a Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed;
or (2) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s
breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the
other Transaction Documents. The indemnification required by this Section 4.9 shall be made by periodic payments of the amount
thereof during the course of the investigation or defense, as and when bills are received or are incurred; provided, that if any
Purchaser Party is finally judicially determined not to be entitled to indemnification or payment under this Section 4.9, such
Purchaser Party shall promptly reimburse the Company for any payments that are advanced under this sentence. The indemnity
agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company
or others and any liabilities the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.10. <U>Reservation of
Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at
all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue
the Shares pursuant to this Agreement and the Warrant Shares pursuant to any exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.11. <U>Listing of
Common Stock</U>. For as long as any Warrants are outstanding and exercisable, the Company hereby agrees to use commercially
reasonable best efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently
listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Shares and Warrant Shares on such
Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market to the extent required
by the rules of such Trading Market; provided, however, that the Purchasers acknowledge that the Common Stock is currently subject
to delisting by the Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other
Trading Market, it will then include in such application all of the Shares and Warrant Shares, and will take such other action as is
necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible.
The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading
Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of
the Trading Market. For so long as the Company maintains a listing or quotation of the Common Stock on a Trading Market, the Company
agrees to use commercially reasonable efforts to maintain the eligibility of the Common Stock for electronic transfer through the
Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to
the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.12. <U>Subsequent
Equity Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) From the date hereof
until forty five (45) days after the Closing Date
(the &ldquo;<U>Restriction Period</U>&rdquo;), except as permitted pursuant Section 4.12(b), to neither the Company nor any
Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common
Stock or Common Stock Equivalents or (ii) file any registration statement or amendment or supplement thereto, other than filing the
final Prospectus and a registration statement on Form S-8 in connection with any employee benefit plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) From the date hereof
until the one hundred eighty (180) days after the Closing Date
(the &ldquo;<U>VRT Restriction Period</U>&rdquo;), the Company shall be prohibited from effecting or entering into an agreement to
effect any issuance by the Company or any of its Subsidiaries of shares of Common Stock or Common Stock Equivalents (or a
combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a
transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or
exercisable for, or include the right to receive additional shares of Common Stock either (A) at a conversion price, exercise price
or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the Common Stock at
any time after the initial issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is
subject to being reset at some future date after the initial issuance of such debt or equity security (other than in connection with
a stock split or stock dividend or similar event) or upon the occurrence of specified or contingent events directly or indirectly
related to the business of the Company or the market for the Common Stock, or (ii) enters into, or effects a transaction under, any
agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the Company
may issue securities at a future determined price regardless of whether shares pursuant to such agreement have actually been issued
and regardless of whether such agreement is subsequently cancelled. Notwithstanding the foregoing, commencing on the 46th day
following the Closing Date, the Company will be permitted to make any sales under any &ldquo;at-the-market offering&rdquo; sales
agreement with A.G.P./Alliance Global Partners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) Notwithstanding the
foregoing, this Section 4.12 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an
Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.13. <U>Equal Treatment
of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person
to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also
offered to all of the parties to such Transaction Documents. For clarification purposes, this provision constitutes a separate right
granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the
Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the
purchase, disposition or voting of Shares or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.14. <U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it
nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short
Sales, of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such
time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as
described in Section 4.5. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the
transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described
in Section 4.5, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information
included in this Agreement, including the schedules hereto. Notwithstanding the foregoing, and notwithstanding anything contained in
this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation,
warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that
the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in
Section 4.5, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in
accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first
publicly announced pursuant to the initial press release as described in Section 4.5 and (iii) no Purchaser shall have any duty of
confidentiality or duty not to trade in the securities of the Company to the Company or the Subsidiaries after the issuance of the
initial press release as described in Section 4.5. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed
investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio
managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such
Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the
portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.15. <U>Exercise
Procedures</U>. The form of Notice of Exercise included in the Warrants sets forth the totality of the procedures required of the
Purchasers in order to exercise the Warrants. No additional legal opinion, other information, or instructions shall be required of
the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be
required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required
in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance
with the terms, conditions, and time periods set forth in the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.16. <U>Capital
Changes</U>. From the date hereof until ninety (90) days after the Closing Date, the Company shall not undertake a reverse or
forward stock split or reclassification of the Common Stock without the prior written consent of the Purchasers holding a majority
in interest of the Securities, except for any reverse or forward stock split or reclassification previously approved by the
Company&rsquo;s stockholders and expressly contemplated by the SEC Reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.17. <U>Lock-Up
Agreements</U>. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except to
extend the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If
any party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its best efforts to
seek specific performance of the terms of such Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE V<BR>
MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1. <U>Termination</U>.
This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect
whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing
has not been consummated on or before the fifth (5th) Trading Day following the date hereof; provided, however, that no such
termination will affect the right of any party to sue for any breach by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2. <U>Fees and
Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses
of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the
negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees
(including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any
exercise notice delivered by a Purchaser). The Company shall pay any issuance, stamp or documentary taxes (other than transfer
taxes) or charges imposed by any governmental body, agency or official (other than income taxes) by reason of the issuance of Shares
to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3. <U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Preliminary Prospectus, and the
Prospectus contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all
prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged
into such documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4. <U>Notices</U>. Any
and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via
email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City
time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via
email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or
later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if
sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5. <U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed,
in the case of an amendment, by the Company and Purchasers that purchased at least 50.1% in interest of the Securities based on the
initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by
the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver
disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted
Purchaser (or at least 50.1% in interest of such group of Purchasers) shall also be required. No waiver of any default with respect
to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of
any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any
party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that
disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights
and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment
effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company. To the
extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information
regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6. <U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.7. <U>Successors and
Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each
Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such
Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the
transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.8. <U>Third-Party
Beneficiaries</U>. The Placement Agent shall be the third-party beneficiary of the representations and warranties of the Company in
Section 3.1 and the representations and warranties of the Purchasers in Section 3.2. This Agreement is intended for the benefit of
the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof
be enforced by, any other Person, except as otherwise set forth in Section 4.9 and this Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.9. <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be
governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party
hereto or its respective affiliates, directors, officers, stockholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any
dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect
to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action
or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or
proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of
process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or
certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall
commence an suit, action or proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations
of the Company under Section 4.9, the prevailing party in such suit, action or proceeding shall be reimbursed by the non-prevailing
party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and
prosecution of such suit, action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.10. <U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities for the applicable
statute of limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.11. <U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a
&ldquo;.pdf&rdquo; format data file, by other electronic signing created on an electronic platform (such as DocuSign) or by digital
signing (such as Adobe Sign), such signature shall create a valid and binding obligation of the party executing (or on whose behalf
such signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; or other electronic or digital signature
page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.12. <U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid,
illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in
full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they
would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter
declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.13. <U>Rescission and
Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of
the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document
and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind
or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in
whole or in part without prejudice to its future actions and rights provided, however, that in the case of a rescission of an
exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded
exercise notice concurrently (if such shares were delivered to the applicable Purchaser) with the return to such Purchaser of the
aggregate exercise price paid to the Company for such shares and the restoration of such Purchaser&rsquo;s right to acquire such
shares pursuant to such Purchaser&rsquo;s Warrant (including, issuance of a replacement warrant certificate evidencing such restored
right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.14. <U>Replacement of
Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in
lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the
Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement
Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.15. <U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the
Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary
damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction
Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that
a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.16. <U>Payment Set
Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a
Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by
or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law
(including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the
extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in
full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.17. <U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or
nonperformance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers
as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in
any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other
Purchaser to be joined as an additional party in any proceeding for such purpose. Each Purchaser has been represented by its own
separate legal counsel in its review and negotiation of the Transaction Documents. For reasons of administrative convenience only,
each Purchaser and its respective counsel have chosen to communicate with the Company through Sullivan &amp; Worcester LLP, the
legal counsel of the Placement Agent, and Sullivan &amp; Worcester LLP, as legal counsel of the Placement Agent, does not represent
any of the Purchasers and only represents the Placement Agent. The Company has elected to provide all Purchasers with the same terms
and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the
Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction
Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between
and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.18. <U>Liquidated
Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other
amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or
other amounts are due and payable shall have been canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.19. <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding
Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.20. <U>Currency</U>.
Unless otherwise stated, all dollar amounts and references to &ldquo;$&rdquo; in this Agreement refer to the lawful currency of the
United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.21. <U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and
every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after
the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.22. <U>WAIVER OF JURY
TRIAL</U>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH
KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND
EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages Follow) </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first
indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>CNS PHARMACEUTICALS, INC.</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 45%">&nbsp;</TD>
    <TD STYLE="width: 55%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name: Christopher S. Downs</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title: Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Address for Notice</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2100 West Loop South Suite 900</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Houston, TX 77027</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: <U>CDowns@CNSPharma.com</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>With a copy to (which shall not constitute notice</I>):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cavas Pavri</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ArentFox Schiff LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1717 K Street, NW</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington, DC 20006</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: cavas.pavri@afslaw.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[PURCHASER SIGNATURE PAGES TO CNSP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of Purchaser:&ensp;<U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Signature of Authorized Signatory of Purchaser</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of Authorized Signatory:&ensp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;
&numsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title of Authorized Signatory:&ensp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&ensp;
&numsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email Address of Authorized Signatory:&ensp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&ensp;
&numsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Purchaser:&ensp;<U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of Securities to Purchaser (if not same as address
for notice):&ensp;<U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DWAC for Shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: $<U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares:________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pre-Funded Warrant Shares: ___________ Beneficial Ownership Blocker
<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT> 4.99% or <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Series F Common Warrant Shares: _____________ Beneficial Ownership
Blocker <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT> 4.99% or <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: ____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed to
purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the Company
to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii) the Closing
shall occur on the first (1<FONT STYLE="font-size: 10pt"><SUP>st</SUP></FONT>) Trading Day following the date of this Agreement and (iii)
any condition to Closing contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by
the Company or the above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer
be a condition and shall instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement,
instrument, certificate or the like or purchase price (as applicable) to such other party on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cnsp-20250513.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOauG2aPty552+YkxvmRzfcnqHyIrvkg8ACqbmyS28UkF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:CNSP="http://cnspharma.com/20250513" elementFormDefault="qualified" targetNamespace="http://cnspharma.com/20250513">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://cnspharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="cnsp-20250513_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="cnsp-20250513_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>cnsp-20250513_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>cnsp-20250513_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://cnspharma.com/role/Cover" xlink:href="cnsp-20250513.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://cnspharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 13, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 13,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CNS Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001729427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2318545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2100 West Loop South<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">946-9185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CNSP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( 'V6KEI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( 'V6KEJ+@4?^[P   "L"   1
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
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MVAO@]Z64YOW$O@0HWN$,_P502P,$%     @ ?9:N6I^@&_"Q @  X@P   T
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" !]EJY:JL0B%C,!   B @  #P   'AL+W=O<FMB;V]K+GAM;(U1T6[", S\
ME2H?L!:T(0U17D#;D*8-C8GWT+K4(HDKQX6-KY_;JAK27O:4W-FZW%T6%^+3
M@>B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/46PQF
MN1BUMIS> A(H!"DHV1%[A$O\G7<P.6/$ SJ4[]ST=P<F\1C0XQ7*W&0FB35=
M7HCQ2D&LVQ5,SN5F,@SVP(+%'WK7F?RTA]@S8@\?5HWD9I:I8(4<I=_H]:UZ
M/(,N#Z@5>D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"FHO409.B1
MP74&0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\
M]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @ ?9:N6B0>
MFZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#
M, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W
M;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9
MHIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJ
MEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( 'V6
MKEIED'F2&0$  ,\#   3    6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%
MKQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/
M$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4
MZ]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N
M6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC
M JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@A
MLO7L^T%.6X.^D<WC_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_
M7G\!4$L! A0#%     @ ?9:N6D;'34B5    S0   !               ( !
M     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !]EJY:BX%'_N\    K
M @  $0              @ '#    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M    " !]EJY:F5R<(Q &  "<)P  $P              @ 'A 0  >&PO=&AE
M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( 'V6KEHL-*Z!C@0  ,\1   8
M          " @2((  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !]EJY:GZ ;\+$"  #B#   #0              @ 'F#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( 'V6KEJ7BKL<P    !,"   +
M  "  <(/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( 'V6KEJJQ"(6,P$  "("
M   /              "  :L0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" !]EJY:)!Z;HJT   #X 0  &@              @ $+$@  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !]EJY:99!YDAD!  #/ P
M$P              @ 'P$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
."0 ) #X"   Z%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="cns_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cnspharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="cns_8k.htm">cns_8k.htm</File>
    <File>cnsp-20250513.xsd</File>
    <File>cnsp-20250513_lab.xml</File>
    <File>cnsp-20250513_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cns_8k.htm": {
   "nsprefix": "CNSP",
   "nsuri": "http://cnspharma.com/20250513",
   "dts": {
    "inline": {
     "local": [
      "cns_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "cnsp-20250513.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cnsp-20250513_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cnsp-20250513_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://cnspharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-05-13",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cns_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-05-13",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cns_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cnspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001683168-25-003575-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-25-003575-xbrl.zip
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MX=?:KCG2.S]&QOT-1V/><.004&@:X$.0SQA'';NN1SIN% X6F(_B7&15O66
M1OX K\_;1M]O-?SV [SC]54&" SL1!S,"M#Z,UWB'.%8S^-=&SZ>^9?NR,GG
MW-_^]?!+8RO@[=K].;>QD'-3](7FGVX4A*ZS2!:T14FN#$!AT\_\<_"QP, N
M<.><H#_0)YW1_J>G=.<V%XYZALA"\Y*-:;!@X',ZD#N/YRX08W_CWF(GUHFN
MQUN7&XUN]0'^U=;"064H*#0W-JKSNY#/&A0JNC B]'S@,_>H3=B8F1"WWF"@
M""L/"]YH:T S0:(?,R)\SE5@&J/_^U^;AKZQ$T!/FWD#UV'$$6M[$8)?TXXP
M_M.HSRA,N,7F$U<U)5JHEBWHMEB8+.?4_/.8=T["WKV%R<CDH](X8?8VJ]4W
MJVK$AB+[V 5'\AR'O<Q-KD5G-\<'Q^-Z__YNLI%)E<SB+32WZNNE+?",?_(2
M\+Q;$:=N2%J>9X-#!_[:\RCY 9AD<"5/1>K')^JK4GV0^AYIB]RTI770U))C
M"HZ'S.S^4Q) 3^F$EB <$ZB2!UTW#-VA>I9&_!U6;]Z;J(?<0><>NI6-!EK#
M]H"9U[@_0:@'*R889%@"M:X[)EUFNR.<*&S$^2.;I2/2XS;8*L(#,%PA V 6
M;GL$?!C9(748N KVA 00. 2]B7A3O>!V@1H54DF0J6Q@!'!\0IU)W-9S;4".
M1A%7<8X144#6=GDS8 PWSYOOF<-\6#8.'0 1R="P53;*DNHWVT\VC8J;3[Z,
M+)^U^8"N1X?<GFS?5H@U:Z'KRD)_]GD(TXD!:.2HP"_(-],;/\)&=V_C1_1>
MOZ^3MMUU79M11Y1BS1CP3+(MERSD_=9&O;ZST(B+/W*"%OVK(&MF!C3Q4GMY
M%Q&$X'6CH<03Y3*UN89[:FOZ!FD?7!"C5BU#QZ<S7,NEX9\ABGM*%#LN+%3
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MU^])O+IZ<T7EYNKT_.3BZK5/FJOWO0J;_K)MY ^*\L2Q3A3X)$)O94RMO;X
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M:^K0KXD=+!$]6/@&*L/2B$7CO@!R?$F)&)>YN-I'T<0=.K<4!,('U\+5JB6
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MU/8\HEZ>P!4PY&RD:,D-YL0CN2W@!29[W*_5X(/F)H&Z[K1&>V<ED ,5;'.
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M?$<F_X"+6'XYF&3MF^L7</A\\;2Q),LIZ\)MV!1N.\4.J-5P3H7Z:5N]BB>
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MX[&:U\C)(0N!U3#^D!>7X+&?LQ40HQV,5,$0 7P7O-'*L!%*W M0:>2QRY/
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M2Q:?A #RW:/ASLY.F_RT+^ 7\;"/;Z()7?F_*]<;@DOVW:,=<KY<ML""2CP
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MF^3JB*308;>;_5@(U^F+N*BG?J2G8>QO9.5'5:K+GZCZ-7;AEFCNV94H<.G
MNG$<S"D,72V6G$B")>2/V[_\\KV4!H:]X<YNW.*N%01W\]U7<LM-R8A;[R7%
M5U+3%2)@S*BLE=K.%5<0RK\WD-!M#8^>@$3_RVT*W>29:4Y3^BC-K2M8?Q'R
M1I]#7>/VK"#OZJJIJ<JZDM-K**&ABPITP!9<<H8>"*B9W=PY +'4U]'(Y!)'
MRH'CL5/=?WX$XBOQ&_MU39\SX2FL-N.;L*J+U1]"#Z]3U>5"1ANE6,>)HEZ7
M'DCJTA8BZ1Y?^%(*W(Z"$I/0B"K?,5[%HR$5<I8E711_5UL2,]#V.^<X!1+
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M6\<?J!N0TM5P%1=<IA<& TWTO9VH[H5<JP,]];YJAT,Q]-=SBZF0#XC!AD&
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M5+BR;=O#KIX@Y)5%%ONH%3B6RX$-'G:WJW#GL$;:$D$PBS^FL\6LN^M=1$V
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MC-Z='MU_^?[D\.@P.GC[YLW;$_C]VX/_C=Z]/SUX-3X[BGX>GYZ.3\YY^CC
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M]/;9F'N>%)7G^KT6G>+MU$-8C((UGPO8^H+U']&61'C$PO"9YNJ&]'SQ3,S
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M0<L)VH#L?$RRRXS4@W\,QO=?#*/!WX;_Q,\'XR'H@BAKGWP#?/>WF >A$A2
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M([Y]1SL19P\IG[2JZ**XLQJX36\ENBK8$+KV7^T3Y8I0<^":- H]-D)T%J1
M7G< XLLP-B9#%2RPC04K=IR3MEK*GH 5GJ)C$3$:Z);56:5R.6'#01CG7)_M
M>;%M7PH?C_F[#MBX_DD1D;$OAV!:ZQI&-Q@^7G^.D%%M'@"]NC;N*IH])7_
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MXJI+.4Q@?$G.$U]@YEP:=N.K".FU'D'_SCD^9W7Q2#^PYJ;+_[QI&7!G6NZ
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MYK1@8R,NHA_V=6;K9<GE>4M0R#4&[Y1GK\+E7@"58K6W?7.D)9QG6Z.!YG>
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M8261:/,G$ $H0I)RG&<POLIHP>HT-@8X8$OKF<WBK#7U5@JZR3X/^;-5QK'
M1AF&YCE:N5<=['"C&%Z25!C6IFQ3$Q(!(TK7RADD\=/T @&9VC% ; J9XDN;
M.?9YG*)3,(%7) A;X#AOK(H[R:E&_[M;;\OVL3!8[A>9)AC T<P9G7_8EE<:
M"&\H+V/46Z?(S')).77#(^?VCJS[- H0.M6>D:EE#4>Q #/DAH1RCV"[([/R
M<GZKG3?MSAW3EZP"F.MF'TY31YI?A[949<NW2CFL?"V5OX"%')0EI=N$Z00+
M[4<G=_62P3!I%EY9-N:"8?<G4RW?VL2L<=^"_C%W4SN]T697@Q4<X>RB4$@X
ME+SB%<3*E;3J-V^TE]%U6_DT:N/W60U1=2=4@R]'=,MBAF',I*;$I-7KUF4-
M5W)8N?OQ3/T&O;998L4]3%V/.- \N'!]DU6HMM_C"3UE1Y\L8Q3-5A4.S(4.
M6*NA;GVKIZ^4P60$4J<!R9#]IA375F',);&X*LT5A"+(;_'N,8JYA6YGH%2#
M:&NX<3(?O?$*V4VQ20+=(_\MHW4(!ER-4(YPUT">4\>#^X+!:DU?Y7ZHN+&3
M7*<!][&T'+8^KA0ZNB<2Z@QA..(B+5<UZ+RX0@=@,+!65\'N]P[(OXT<'Z/C
MR BP4V'TI_O_RS%5)^S+N!'>'1)EV=F8A.OQB D3MBWE%($%3"WABI9#6U&(
M+G9QY800GK1[!"9WD1I=6'Z9ZLX#Z/!SF[Y^)+K 6(!N2K"3KME,U.>_:@W&
M6&X^PB_KSV<NGGH8%5N.1P'OOHFK#VEC9(JOGTH*40$:4TW]Z&W"AL,#^6]E
M+%NDA.*KG23F0;ZS$J)BKWA#+6-*!8"!IZP$PI9F,I5;X)I^# V*^B!GL>"Z
M56M,(6M\+\V2W<)6\HP*;T]*C&?"<YS 6+84P!VC00M=[/L]#1]M;.0==*(P
MNIC:"T%UEP1^ZP+Z^/^6AFU!=>3QE=? 5K5.%>70Q+"W:5%3D26@<G?X%4-6
M*O5\47$A$QB;6K!V@;5^(Y5=*9USV]'(1MW8 LL"T=";:;@B1R:B,$2<UHN"
M4WWC"T[!=]M,F&P5TW?7']/-P! ]B"/"7F_>#6UX94HR#Q+:#=SL(N6 Y6R%
MZ'!N?UUJB^NUU+4@U31<R8(S!I3)HAZ7F#3'\_6&QFC+9#-4)EA1DIB^]/H-
MJ0RRH,CJ;HV^,"!IM4.PFI^5\1!H\LQ[F[)V)?^NN?6PID?)P=-:IH!MB65L
M_UVWM44[7P8M?ZODPD2#&89#F9KT2.DO1-)Q=!I"5T<15'?K4BTF4::(332N
M;Y':#A48Y$#DK).R0?(ST;]BC5CT%PJ8V"0SP&%68N\'BV5M/7HY7]<8YT"E
M19^WFP_DX$5'JR)'W==Z-]8^J$5Y[B^PD5=4:J%SW3IJWK<;V]'H;+$O[Q)"
M0\W!OIMT[51"D?:]T/<^5KV:,BJEMO#/9@:R6:_537Q3C8I&"GW:]/BB-"TD
MF;ENU"ZD8FIE?'!"Q2CG,64_NR3'@=@=$U^, W9BMJ%V=$?2HCY5=NE^\6R
MD8U%8(R2PL5&N.97Q$:ENU:LT<&1BS0"[X1AL1H;WP=E3;=(4:8I<:NU[C#"
M?>V)E]I,35\KBSB4*X8R?YA0@%TSQ08;,;2$BZ..^SNJE:I!/!Q9W7.,P+$
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M?IWR@79C$:?]#I5Q,,V9^@.-:(&=]M@(23\0QZ,/<&/*"0HRA4T)(I!24"U
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M=UTWU+Q6 90V3XV=X*!*257VL0KM8FP#I"*B4'EAS!$;.00O75G35P$MLLG
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M?Q)25WP%!$ )B#H9UHGA/HW*ZM=U=GW!]<[L;/-Y&H98L\!^_**FFCH'JO+
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M,1R?H#27K"\#7>K469K7Z0VNKJ&EC,L8E!+JG4U9JV8)K\%;\@+#(Y)O?I6
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MF&J(B4-?(!88$S).#0[ ]2IPY"']0<*ZH,+R7B*@AJ$XY@[2"*2?@E$?]N(
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M2#=;+L4;!]XP!;I"/)[;K*GZP]0L"[U>^#'G(LN#:S,YR]Z38R'^OP\=H(D
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M_N%*W=G2';RVRX&5$$4CYP:(BTP:$TH4:!NQUSX:5*$ 3TC\)H$F18_Y4?1
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M"X2*#B\)KB ;UA7L#UNN@7W61^3%'XHK-&@.1?!AR7[?:KW=5+WAB3;48_)
MOTD&WLEDM*V-R[X\[=0>MJQCW'8,!SEN'7&TU2#GECEHN+[%<R-0@31]3+,4
M@O0%T(;OP.IP%T^"5$99D@4=PN!!X ^!X^EDZ'B1X]"X2'&XSP(6!K\$87F4
M9!^%JU*.#!&J^0YGWW5(Z70.\#5U(4KQ%D*%O8!"\[2YP36)<H?#[3+@&=K%
M.'%@[ODA/GDOL,#I'5C@<X %3N_  E_PSIO]>B1LU'CBN%2/MU[1*^0H!/>*
ME).I5B[D&(^O=1W;Z+JG=O%)]$ZN@F_9*0QS>(/I9 "@=J[6^AFW^E+8\5 I
MV,D#:BU412>/L$R_4;(=/:*;FS*:G1Y%VS2ID/$P7:0N*+VDSB"2QIBI=UE?
ME508O@%YE]1H/'!"DI!LB4H;*E-0BH,CV*NT\.!L!;AGLR"7Z;\A.AF+K$[?
M7V7SS$ _";2W/T@!C^C+E&;%9<3VQ]_&TNC.5GD%Z Z/A, ;&W)F;\\$W,Q]
M0CB0%]=0+%+RSA.V>XD@,RTH13M3W[T*(IL2QS]R-BG7B#L4!L=ZW3I6%("-
M1@>A@/3])JNL42A-:MQ P*I7RSVK+"4BA;+C7JQ;,J3+<:SF+N#^X&[ :\,=
MT>$(MH9ZS["DG"6)(S:$Z*-@7M/5SR;@I,SX=R<G;X&"NH3 'NFZ#X&"]LIW
M"@HXDN<D[GWJ0O($B2!DU,G#AYA"&0-''9BY.GLG!=52)FI*2$P5-=9'HZ5%
M:\!S:)HSH^LNA,H/9BXUB&S7D("B&X'B0]=&-=]^22FC^!A,<,LN-;D>K(MK
M.;EI]RV#R6@WM\HK9K@%S+LJ]B1$<JF")V2.T)8:$+K7;,?1!>JE(8'"">;;
M%&I%T4 IGWD%PX1FFH@MT%7UW1)^+HAKC,181S.OZ+\_.WMM-;QPD7$SL(16
M /8X \&SNE_"GI'9Y3,5W_8:F>.6+@F4.(XS3Q4IW&L\HGKL]04N0OW-TO#,
ME'M3Z*LM$EADHXL2'QX %#!H4I8-W]0>^/CV4HB89%5.,8Z:Z[- $,/P?,+2
MZ5,W99T-)5HI^4A'B-E! 1.UM!,M? ""$ZJ*Q%#2S&&*6BY 36H08U[>U.X>
M.B<-GA34$BY65>C4L')7>"EZV5%$H$ &@!Q-F;6^?TPVU[V4F$B1I\5PPQR:
MZLQ)=3I.XZ=TF->/IY.?"VE8 B(]OV9QOA2B;XF(/X.S*B\W1L]>A%T?91UA
M*J5N]E# MLD+IMG&#4I*J7TD9J.O=.UF-]$P*D:TN9;\*%8Z".K-)Z".HF2J
MI5@[]15,LK3T\N&MCK^X2I:1UKXQD<IMY"DH!\.>TNLX3+C28C_>[2M2Z-I.
M$)ETS)3.4,> 0A2HFV<;LH08T>SLB/LH@C^\Q2-( ':+18715AQ_4:?F,;)3
M0>7S5"!U"&]:Q\]N-#.=")NDQD0(=?#C&.;LR1$2D_O!=IE0YJA<5CG+SK?/
M#$)Z@XO.^FZH0FGFW-+/"D?\@0:<$&F%1V?<YZ=VZ?8D;YB3%54YN#XEA7'-
MB3?"5BW<'@.WG$Y<22RE*01A2ISS*3/]+'%+*%DG$OJ@;G4!64<BA+F^ID.M
M:T+<RU@2'N&3X"SQD5S;2I&<34F0;$UN@8Z.()BKC!^WX!/")(O/.:([1HPO
M"$E9K6")5-HQAX/T9RN<,T('RL:VDTRM(%#T+LW(.4Z7<BK7!0B/5C!B6^ I
ME';9F=512!G'BKJV%:>U?FM1#:XX+;_"V6IPQANL7%4_Q_2\ZN45LAYCAY?,
M;EKLV.@HUZTA)B<I#IR772H,9\BU(B7\ K;4X/1>;;6856'T W?USI;!>!]8
M*MW^*CT'5[5&B@$*QU1O.>SC@/]>2><JL_\]G3XI8B6^ZVH4KP>&PD0!U6T/
M8174_Y* @MYA&2L44Y) ?[IS@BD1T')NY_",?&L& Y=@.PRDM,>BB),CQ^#S
M+-D.0 KHICL&<6A&SYJ,GI<P6PS7$<[,D918MV/7^DBS8D3()5SG:)IF9)?B
M"MK&CFQQY;./L6WE07[C-6@$&02L95>7OT<NRQ2\*^.VXWA3I\97R(=60.G
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M5VQ0::-0>CQRJ8JUU2C_NB,P*,&9;E-)Q=2AD$VV/9K#^@!/(P#Z^8);DRT
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M#*?./9I[" U.15V6-!N3X>W"HT4&"D"X(QHS=#G?W5"5WI(DU]=FI2&OY6.
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M2?@P<,$L(?4G[<@D^@O?YUJA [3+>T]"$[S"U&32P0DQ<$<Z#+@(XTAZDY)
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MO"<.M4@ORR83(6K#8YZK)2>@.0W =,&\N31K%T2A.I*/^H)_S*?"OX[4:J$
MB2'=Q/5"Y!>NQ'YP/2"LWK0FJ+OZ4TXFJGH;J+W$&D_'0Q+B=88;N9G>TT/U
M!'8G')@S/DM3YNM(WA.\I$4!_/R=2YJM2M<)V89\/J0]U4X:W#V8]^,0?3'(
M)4O0+#2(75B6*GFP0 ^UQ,_'%\?C#:<Q";WF#TR':NP& L.#DQ9KF 60)MU-
MTD6>:/\VMW2E "8X>#IMQP4R)U8LY?/0M,:G4N\1H[7"!MO4U\!8;M2.%"G5
ML:JM9BH-Z1(2*6V=C\ZC=$E'QZBOF.YRF3)TS!>UMF0."(@L?.VH]];>.J2F
M9U1=76/!N5K29?FN-NUFS0J V?D-JT>'.K,$R2$6R8IY0KBV%>8\Y28IXE?I
M-RIH*??MO0"]L1W_9I-OM1,I"@M,F[:@V>#'2F+$#4;\)"H]"F0FECC\BFPN
M;87NFK/:]1"[K)PGK.G9#O([H\'>%6QO8ZG:" WUH:FMU8K4UG/9JT_!* &K
M,'HM]+PUF#%/*\HO(_U$(UIM/]9UCLC?PNTR9.61>KH,&'28X889/#FH/\YC
MTKD;J@=4:6/!?N*=94@+9L.I!T(!)O"JE8I200B!M"^S%?5.P2@9YORX$,L-
MTOW,$:^8-J6J#G$'@9J$25E@.^B,@GNN_[FH-)> <+?4S3UR)Z_F* E ;7H9
MA^-YEBI7$[AS*-*PD8R=! F)+PN)ISB^>Q:5$C\@W3>_HZ(3$!V4;]DBMR)T
MI88[IXS,.+V2"LAW@#G*U8 W@"P^2$Q_I,HLZQ-@4R-P2G=<'RG__;*GKM3"
MX3IVU_1[%3U_^OKLT)3%Y24C!(5EPP+:^]U9\,=(@IQ2MUZ'*A>DBZ%>0=P)
MS=A KBF KW05"9X!Y YWM4"L=((##]EC+$EHC#1=_/F!S?K5E<RZ2I[TT!O%
MUTPG_9RO?B)5"QY'!V?'WG@!+1/H 'MP$ED1@!>8YDH6 OYM@@D8[K:-W7RJ
MM5N+>5I<8I+4P0^&,&R#Z+,]X#\- PV"* \8E&U%9T+PBGT<A'\; I8,5K*O
MP#=8D&+L''8S=A;(@E'XJ CAB%X1&>(^Y3M&VO,71P=>Y"52:O0JU@UI?!=8
MA0/R<(!K/F4$8S=2'_Y[AXS]'].*%\J"VEP@W*D'&-.ENS%+-\P9A&$\G5_W
M/DQ\@VO6"Z);#N$6)-C0=)+00,B<T*8Q >3(6;GTJ&%)N.833%8BFZ)4I@^O
MA#U[R1 @D^EENN"9@5Z'>/9V)O' -.(A/GFOQ/O?[Q+OGR/Q_O>[Q/L7O//(
M'^S97U31)@!G=]ZXXT7A56?B5;*9?E9LFRM.='4/&JH!JU-NRR$X4SDBF=BV
MHJ)*/)0UH3.=S$R[8T'NU0C=4[JYA\<GCP1'>11+Y$YPY]K9V5A'/<RN9U>T
MO,'&$J2(&3>SJ]\-_+YD<Y+#$$KOX ]G^I)IBQ%#5DL3#C$ I"JQ3JG&!5NU
M<B;P*TY65 TZ&6,0-7(L)4,$[YM=TSGI2$3\SQS!F/DL[!]KO&3L@%7FVJ+:
M_\!%L1R9&X8D'W,D89,PL:W4&98;ZK?,J#O7K]D:43W^H1 PZTG3N1*DVW?I
M F4373!:<H<0[#/CB'4(&8.<G\:%)^E$3;[YEZA-18]#2H8W1-ZA J/GU->1
M&BL)28>\_*;*%J/X#G8,\^T]2K(MS0,?*]DEVOA&1@S.;U&+W], 2E;L]_H^
MNNUBD:&#P)37 5P5ZRE\",O38^-[2YLT>38M5GTLI;&D4$->W!6(&E+-CAG+
MA#M"G[-$E<'8='Y0071LA,)UACOS;WDR-H9M]APR*[&MNC+[R"R,.3ACO%O5
MTG>^,-])V@2[_5:!.D'1,0D7CN0*?D1N&:M0 =N8@HE>>:Y'P6+^_ C91*^3
M*BO;FH@E:UN$P.%V[Q^8W4P)49\WCUVJD!:&#(L#H6Y<%.D^<JU0P5WD0H
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M&"J,Q\ZM5%?49-@S"+!E.! U;:>[;XN-NUE?[5(2!0C2_(412IY[<Y#,N9"
M&">;)+#I+U2<M[I13 ;Z#9FS+2LL C G;UX3$=_!NJ(91[ 1\X0S_K(E0^)F
MJQ<9GNZQB #@5O<R"=A9[6NCF1F!*8&Q35>$LD(K8[I RJ"WYTR=\Q,IE-+R
MY.(PZ@JO,IL85VK3$ 0XX42E+'.6 ;?0(R8S:6T+DK3,8R@B*FVM&H_1-+UQ
M:WT/U[J9>R!2W-XZ4%R8&%"*]&WN KAL^&+WW\,>DA^$""N8+Q% 9=29QY>T
M8$J#JZLU'T*5=7#:HX$2LVQ0Q56!<!N_ T61;Y_]PR)*X(GME8@QA#BX^+"B
M<D/F9\>J/O>*\M[[^2IS^[[OM]2^IO*MI826I&6M;)RMT3OB?)T:L\&Z1 3_
M#8:OWWY]EHT4JZ_/I'E"<Y0*B^8W,@DU4L^^J3ZR=5?;6S[-Q7B'!A=2PS$O
M B^W4RFS'WZR@RD,"-D5-ZF8R,C3@_T^M$#'8L#**"D'['LWU)T]2R9 J4]3
MM&:6UE;A2>DD)^)"G*;/<!G:&C@!"5-]8]%-=X*0J76Q9F[N-QDT_K5)L=/K
M-U\;.!874;UXC,<8[+(KJO .8&TFI-+LL(&_2#,X+-10&UKYMJ.&-Q"<3Z3W
M#+T9)YBZ=2;6;%7@ XB@&LH\.R1;DA!_X7.O8'!CQ_ 3U%VWGF&)"0J.L=QV
MC9%_@.'5^[P-BY"M8?6K=Y&/<2$>#D]SK-#P1@U7L<I'Z23Q<2)9 ?!8NO:%
M7+9A_=8FBJBK[9/)^#!KH4_XK#5/2&I,;7=Z2,TH1WXT;E+M0-B2H20*-'V5
MS*=4GCJ/;R ((!ZFT*?Y^S(-^8WG\:<6.C9[=1*N- S#PE6!!9YFV=/G\$5I
M.#RK>?L4Y81,6V4,7;X5>&#&!W5YV3)N7#7XP2Q>**-Z.'%T3*SYE) ^PO:6
MBI[:Y2L15\LGC#IY^!<?N @-UG[+HI%#U"R>!MD3328ZV\'L;6^UTSUVW5'\
M0NX1 -6>=]@G;>\K)I 6T*"($UD-W8LK9#""H:D9\,;$;UN%H?UGEYPYENEL
M:EURIF>D6P"'DT P75\G\QB"TN[%-LP@?^00BJ^?(!2? T+Q]1.$X@O>>:]V
MOR$GW-8TG%']A+.+.5WAE@+*#RC\7&@KF)&O$5O/"^.>=ME8]5K0OGHD 0X;
M@0=,-#Q0"C?Z"K,-1]XCD< L@O@H*%RR'Z4\5L[ &*<9>P#+/(7H\A+>;">H
M_3 J7'#;\3.DND1=GUY 6XG,R<X*11"$LWRS6JT-7&@,)H2"#\UHQ]-\V13[
MZF,,61TU/RH3";%Q? "N8->Q2[:I0PIH;Q W^].')UZG1;5**#(/M;U86FRR
MM[Y H=TXT!H&/Z6^UJC%__,,)7IC;]A=^VKW]2Y5=&7/3IENI9$EY *5-J>Q
M%K9J)V7ZG12VXF8HJL9':VS"1V+!KW;WNO*+]6"#N'VI96@Q)P!PITIU/=82
M$IP?3QTQ],)]P$6''(5!YP&C8^T,0,S*KDC^OB =U($(O*AYFER'T'\OF],1
MJNI''![FJ#)+7-5J)4U(C _'1-0W42,U29?>YJ^KZS),Q!KD@OQ E$3C2S:L
M$X8%; T&+R$H7T)M+C=2K1&#,7*?WO L!<Z8SKP_Y-!AJZ&C.]-QKG/6D^!>
MV'?D."!5R=T6-B2^_9 4"MRLCI(!GHF:1\DQF.XUW3JUX(%JE=-T13"=>G@M
M9%'JC(G1'7!K5"RZ3U ,*X^Q7W?LQ(/W@5*8.>H>J!S1."XA@S+CHG*=X.VM
MKMWF*:644JPV%46R((HUS4#6*'3#1><O6W8;Y0E(Q1%0?+06<=1/%ZYY,"='
MYW(-"6##0'8H^]V&R7,6R&KNMG*2KTKA1<"@C2$.9V%=?"_,6P3#W-4O#A9H
M"8VX_\%XK$F W.W,B>YRY #UPP.?.9MF=WR+=L=%2>" 4U+$*P.#H[TBMHW!
M4NY/6R_;7)HKB;XEE4CPE<H.L[W5D0CV["U8=IH7*'(WB9=IQ3!#80M7HGF?
M.$84HA[%T $.'M/3O\>XV4P0FB [4LX$J3*KXZ3-&^EM,4W&@ "NE-UC&=]H
ME3J>:>X7<,;PC3&9%"O#>9\FGM$@ATU/A/FKHA'TU2<&-+Q%8IYG-04L[J56
M82^$&+XB##/J=?UULEQ4;KW7IS0GSW213%DL5 8J (BY3P7_'CK_Z]K-+UX%
M $R1=JR(&XL\VJ[#$(D((T!:IKV&R.:[_=,!_.WDW6#?Q@PW;D=_MRMUMX96
M'M-#=:F840C#J0L%F>)+UVJXD]$&%^IZ<N @7% _L)F%-4C1>?,@)"98)(MQ
M$A+1>&.!S"RTZG<T_69<!:%!B&;(R ^TJ<"=I<O-V='Y7&B9"$ &#U8J="R?
M1RLD2"[$$88&%>6$- V!IX*_<IN"7IQ:_G252^"A;)!F[9B<_"*),PZV*XAR
MKQU+@R.@>)OG;>"HGM>P;AOND!S#6V2-<<=(CH[\[QKNJ&NTF3[SWQQN_02/
M,F8LA$E_!Z;"O9X1;=;1=Q,!&2@K$NP,\V*!/II*WDH"?([,NGU[2O?MZ>I5
M.*$?K@_ G0:?F<8+-[KX^Y)]!&;;+5$.PY!,N]T\O60_.UX (0$00:53LE+D
M4,2F0"#6-VB \7'EICI+;I3Q9"9;AC[NF94O^3!0J[;FKN#H$!1T)< LU]T5
MT%6L2BVM=X8Y)$D ?<#H3F\U0IP6\L8SZSO4ZZ(A36OJHBV'F&$7:A8LIS:'
MWL'A/>Y9/H=4[.^I$"U9)Y#7@R3SA).CA@)9L%T3NCG6@1*I:@,"JT,[KW*E
MX<DB2V=<9Y2E26A/!_^.2(X=&DX2MB7H9+B 3W\.V&PSQW';[+9UNJN2OF^+
MX-$+$O=90XD!N6,82PR0)3ZZZ"4U.A<Q^MP:^B&LG9TB:ML+WJ%J46MK\,)8
MQ0)4*NWR>=(<!-Y TKJK*>$"Q/2J&VAW *14[ + )L)U)"I!Q0QB*.77CRX+
MD K(DDMW!I$Z!'' S%;SR/EA_.@>%;3Y3:!^T[C(5\"$H%LAB)YA_[#0W0!
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MOW%7R6+PJ3=:3%17,>?1$IZ:LAG (T=;SV 61J]6Z/D@XH'XI6%O3+N:#=N
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MPEWB-?Y41Q*.)V'403@L]8'7 A=9PNOZWE&.QA<Z:D_#C]EHQAUZ*P1T(48
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MCSMHF.T!3U N@9+I#N:+"PI3=YM>YQ-D\"Y7XT7JP3?ZY.VM?[F[MIRF$[N
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M\ _OCQHT\K#4:#!(%L!;36YR0!=,Y%0-!!!)<1=,!+%N?B$!P44P@5&UWD_
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M8G.%722H=.N'>"[F2T(XE]=,:68N4PAMS[E"!\,!%/];+!.$[@2A TK8.-\
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M9=0*S6LUV_XJ;;5WT* @'2J*>:H,E1&A:E;#URK910FI0TEG"7 74GM7=*!
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M2_01%!&.\GP9C7)WOD8CY^<GT7?/GS_@@S[D "V'3_TS>OWZ^<O7CWE4AL!
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M<\G[K]Z>'/P".-.O/IS_=/3F_P-02P,$%     @ ?9:N6IABRO4K P  Y0L
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M<GQZ".8?P;%AC^B"<O!-+=!T4S6]_ -02P,$%     @ ?9:N6EZXG>G]"@
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MJAV52A8@**:W/DR4W@LDLZT0#=?PC -+G=V4[3%;W9\%=$& TF.N==>VD#=
M\30#7;(LR?;J<;J;[69%A*5Q;8DK-B!SF@FS/ @6 %,F X4,*1TJA%YZ7M\E
M8)EZB!%LCBES2X#=9)."IB8@$JS& !H.VOR94B]$S.3()#"=LYCL?B%[L%TM
MG5LF )M-* Q10%38G0%8E&*4JY&4>P'C3B0;+/:+).J9*MI"MVA 1IMLF*J
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M:8H +R389:Z'?IM)<_BO:X) H,-8ZZ2DE"*M]?%"PF'*6O<O M;>%@'KGD7
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MMPMDFKK%1#)^&LVL:7V7F?SUI;9_P9L&P7+0T& NX@081[H*TC\7>M'D:O5
M)U2Y:0J/=&FN;$-/X8LB0'%H?%#?* 3&4!&F\\Z!KQN[P;VAMOC&_7)O8;5;
M_@=02P$"% ,4    " !]EJY:W#'?07,;  !AF   "@              @ $
M    8VYS7SAK+FAT;5!+ 0(4 Q0    ( 'V6KEK0"J:.42H  &K&   .
M          "  9L;  !C;G-?97@P,3 Q+FAT;5!+ 0(4 Q0    ( 'V6KEJ#
M(@=3&D0  %&$ 0 .              "  1A&  !C;G-?97@P-# Q+FAT;5!+
M 0(4 Q0    ( 'V6KEJJWV>LOD   .UO 0 .              "  5Z*  !C
M;G-?97@P-# R+FAT;5!+ 0(4 Q0    ( 'V6KEKF;7UTHJD  (&R P .
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64$L%!@     (  @ [0$  "J+ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>cns_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cnsp-20250513.xsd" xlink:type="simple"/>
    <context id="AsOf2025-05-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729427</identifier>
        </entity>
        <period>
            <startDate>2025-05-13</startDate>
            <endDate>2025-05-13</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-05-13" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-05-13" id="Fact000004">0001729427</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-05-13" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-05-13" id="Fact000010">2025-05-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-05-13" id="Fact000011">CNS Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-05-13" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-05-13" id="Fact000013">001-39126</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-05-13" id="Fact000014">82-2318545</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-05-13" id="Fact000015">2100 West Loop South</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-05-13" id="Fact000016">Suite 900</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-05-13" id="Fact000017">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-05-13" id="Fact000018">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-05-13" id="Fact000019">77027</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-05-13" id="Fact000020">(800)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-05-13" id="Fact000021">946-9185</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-05-13" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-05-13" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-05-13" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-05-13" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-05-13" id="Fact000026">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2025-05-13" id="Fact000027">false</dei:EntityExTransitionPeriod>
    <dei:Security12bTitle contextRef="AsOf2025-05-13" id="Fact000028">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-05-13" id="Fact000029">CNSP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-05-13" id="Fact000030">NASDAQ</dei:SecurityExchangeName>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
